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                                           INTRODUCTION 
 
               Pancytopenia refers to reduction in all three formed elements of blood- 
erythrocytes, leucocytes and platelets. It is not a disease entity, but rather a triad 
of  findings[anemia, leucopenia, thrombocytopenia] that may result from number 
of disease processes. 
 
The pattern of diseases causing  
pancytopenia is expected to vary in 
different population groups with their 
differences in nutritional status and 
prevalence of infective disorders. In India 
causes of pancytopenia are not well 
defined. 
 
               Clinical features are those due to pancytopenia per se, and those of  
causative disorder. The presenting symptoms are usually attributable to  anaemia / 
thrombocytopenia. Leucopoenia is an uncommon cause of initial presentation, but 
can be the most serious threat to life during subsequent course of disorder. Major 
diagnostic problems occur when there are no specific features in blood to suggest 
the diagnosis, or when the clinical features are not specific to point to the cause of 
an associated feature such as splenomegaly or lymphadenopathy. The prognosis 
depends both on the severity of pancytopenia and on the nature of underlying 
condition. 
 
               The most common etiology from studies in developed countries have 
been aplastic anaemia [1] and malignant myeloid disease. [2]  A few  Indian 
studies however report  a high incidence of megaloblastic anaemia. [3,4,5]  This 
seems to reflect the higher prevalence of nutritional anaemia in Indian  subjects.It 
is important to investigate the etiology so as to  formulate a rational approach to 
diagnosis and management. 
 
 
 
 
 
 
 
  
 
 
 
 
 AIMS AND OBJECTIVES 
 
               To study the etiology and clinicopathological profile of patients 
presenting  with pancytopenia  at Christian Medical College, Vellore during the 
study  period. 
             
 
 
 
 
 
 
 
 
 
  
 
 
 
 
LITERATURE REVIEW 
 
The study of  bone marrow failure is traditionally dated to 1888, when 
Paul Ehrlich described an young woman who died after an explosive short illness 
marked by severe anaemia,bleeding and high fever.[6] As a pathologist,Ehrlich 
was struck by absence of  nucleated RBCs and the fatty quality of femoral 
marrow, in contrast to findings from the physiological response to severe 
anaemia,and he inferred from the morphology a mechanism of  failed blood cell 
regeneration. Vaquez and Aubertin in their 1904 case report of “pernicious 
anaemia with yellow marrow” first named the disease and emphasized a 
pathophysiology of failed haematopoiesis. [7]  Pancytopenia is one of the well 
known haematological manifestations of  hypersplenism.Challfford [1907] 
introduced the term hypersplenism to refer to this concept.[8] Tissue from patients 
with early cases of aplastic anaemia could only be examined at  autopsy ,and in 
practice, as reflected in medical literature of the early 20th century, pancytopenia 
was often  equated with aplastic anaemia.[9] Adams E B [1951] reported 
pancytopenia associated with  idiopathic aplastic anaemia in 27 cases.He also  
reported pancytopenia with aleukaemic leukaemia  in 3 patients.[10] Lorenz et al 
[1955] from Australia first described association of aplastic anaemia with  viral 
hepatitis.[11] 
 
               Under the title of ‘familial infantile pernicious like 
anaemia’Fanconi[1967]described a  fatal autosomal recessive disorder that was 
characterized by clinical picture consisting of  pancytopenia,skin 
abnormalities,neurological and endocrine disorders,chromosomal  instability and 
increased rate of leukaemia and other tumours.[9]  
 
Zidal B L et al [1977] reported 7 cases of hairy cell leukaemia ,presenting 
as  splenomegaly,pancytopenia and recurrent infection. [12] Howel R B et al 
[1982] reported a  subset of  patients with acute myelogenous leukaemia 
presenting as pancytopenia with  predominance of granulocytopenia. [13] 
 
              HIV infection is associated with a wide range of hematological 
abnormalities. The  peripheral blood findings and the morphological 
abnormalities in the bone marrow can  simulate myelodysplastic syndrome, 
myeloproliferative disorders, and T cell lymphoma.  A study of  peripheral blood 
smear and bone marrow findings of 42 patients with HIV  infection over a 3-year 
period with the aim of recognising the morphological findings sufficiently 
characteristic of HIV infection revealed  salient peripheral blood smear findings 
of anaemia, bicytopenia and pancytopenia. The bone marrow revealed trilineage  
dysplasia, plasma cells and eosinophils, increased megakaryocytes, increased iron 
and reticulin fibrosis. In two cases the bone marrow revealed granuloma. [14] 
Patients with infection associated haemophagocytic syndrome have fever,severe 
constitutional symptoms and blood cytopenias.Pancytopenia due to 
haemophagocytic syndrome as the presenting manifestation of tuberculosis was 
described by Basu Set al. [15] 
 
NORMAL HAEMOPOIETIC SYSTEM AND 
HAEMOPOIESIS 
Sites of blood formation:[8] 
 
              Formation of blood cells occurs at different anatomical sites during the 
course of  development from embryonic to adult life. Production of blood cells 
commences in the yolk sac of the embryo, but then shifts to the liver, and to a 
lesser extent to the spleen, so that these organs become the dominant sites of 
production between the second and seventh month of gestation. The liver and the 
spleen are then superceded by the bone marrow, which serves as the only 
important site of blood cell production after birth. An exception is lymphocyte 
production ,which occurs substantially in other organs, in addition to the bone 
marrow ,in adult life. 
 
             Haemopoietic tissue fills all of the cavities within the bones of newborn 
,but with  increasing age ,becomes localized in the cavities of the upper shafts of 
the femur and  humerus,the pelvis,spine,skull and bones of the thorax.The total 
volume of haemopoietic  tissue in adults is 1-2 litres.      
 
Normal haematopoiesis: 
 
               The bone marrow is rich in haematopoietic stem cells (HSCs) that have 
the ability to differentiate into a variety of lineages. Multipotent HSCs may 
become committed lymphoid or  myeloid precursors (common lymphoid and 
myeloid progenitors, respectively). The lymphoid  lineage produces T cells, B 
cells and natural killer (NK) cells. The myeloid lineage produces  erythrocytes, 
mast cells, megakaryocytes, neutrophils and monocytes, as well as cells not 
directly  associated with the haematopoietic system, such as osteoclasts. 
 
 
 
 
 
 
                                 NORMAL BONE MARROW STRUCTURE [8] 
 
          The red marrow interspersed between the trabeculae of bone within the 
bony cavity contains  specialized connective tissue cells,reticulin fibrils,blood 
vessels,fat cells ,nerves and macrophages in addition to cells of lymphoid and 
myeloid series.  A supportive frame work  for the   components of bone marrow is 
provided by a network of fine reticulin fibrils.These fibrils stretch from the 
endosteum of  the bony trabeculae to the  vascular sinusoids and appear to be  
produced by the adventitial reticular cell.Arteriolar blood passes into the 
relatively large lumen  of sinusoids lined by a single layer of endothelial cells. 
Entry of newly formed blood cells into  the circulation occurs at this site. 
 
                 Fat cells make up approximately half the extravascular volume of red 
marrow, and  nearly all of the extravascular volume of yellow marrow in the more 
peripheral parts of the long  bones.  Distribution of fat cells is irregular in red 
marrow, and an adequate sample size is  necessary in order to obtain a reliable 
indication of the cellularity of haemopoietic tissue. 
 
Bone marrow biopsy:[8,16] 
 
  The advantages of aspiration are that films prepared from aspirated 
material can be  examined almost immediately, and the morphological detail is 
superior to that in histological   sections of core biopsies obtained by the trephine 
procedure.  The bone marrow trephine,on  the other hand, provides a more 
reliable index of the cellularity of haemopoietic elements, and  reveals certain 
abnormalities such as neoplastic cells or fibrotic material which may not be  
dislodged from  the marrow cavity by suction.  The information obtained by each 
procedure is  therefore additive, so that combined data is of greater diagnostic 
value than that provided by either procedure alone. 
 
NEEDLE ASPIRATION BIOPSY OF THE BONE MARROW[8,16] 
 
    Satisfactory samples of bone marrow can usually be aspirated from  the 
sternum,   iliac crest  or anterior or posterior iliac spines.  However, the sternum is 
no longer favoured  because unless the needle is correctly inserted there is a 
danger of perforating the inner cortial  layer and damaging the underlying large 
blood vessels and right atrium with serious consequences. Overlying skin at the 
site, is cleaned with 70% alcohol (e.g Ethanol) or  0.5% chlorhexidine . The skin, 
subcutaneous tissue and periosteum overlying the site selected for the puncture 
are  carefully infiltrated with 2 % lignocaine.With a boring movement, pass the 
needle perpendicularly into the cavity of  ilium at  the posterior superior iliac 
spine.When the bone has been penetrated, remove the stillete and with a well-
fitting 2  or 5 ml syringe suck up not more than 0.3 ml of  marrow contents – bone  
marrow diluted with a variable amount of  blood. 
  
              The posterior superior iliac spine overlies a large marrow containing area 
and relatively  large volumes of marrow can be aspirated from the site.  Posterior 
iliac puncture can be carried out with the patient lying prone or on his side. An 
advantage of puncturing the ilium rather than the sternum is that the patient can 
lie on his side and cannot see what is happening. 
 
Bone marrow films. 
               Deliver single drops of aspirate on to slides about 1 cm from one end, 
place the  slides on a slope to allow the blood to drain away.  The irregularly 
shaped marrow  fragments tend to adhere to the slide and most of them will be left 
behind.  Then make  films 3 – 5 cms in length, of the marrow fragments and the 
remaining blood using a  smooth-edged glass spreader of not more than 2 cms in 
width.Fix the films of bone marrow and stain them with Romanovsky dyes as for 
peripheral blood films. Some workers  add the aspirated marrow routinely to an 
anti-coagulant, eg :dried EDTA, in a tube and prepare films on return to the 
laboratory. 
 
CELLULARITY OF MARROW 
 
 The degree of cellularity can be altered within broad limits as increased, 
normal  or reduced by inspection of a stained film containing marrow particles  
and for practical purposes this is all that is usually necessary.  As a rough guide, if 
less than 25% of the particle is occupied by haemopoietic cells it is probably 
hypocellular, and if more than 75-80 % it is hypercellular. In one study, by means 
of point counting of sections from the iliac crest, the range of cellularity in 
children under 10 years was  reported as 59 – 95% with a mean of  79% ,at 30 
years mean as 50 % and at 70 Years it was 30 % with a range of 11 – 47 % .[17] 
 
CELL COMPOSITION OF ASPIRATED NORMAL ADULT BONE MARROW 
 
Cell Classification  Percentage of Total cells 
 
 
Granulocytic series  
 
1. Myeloblasts      0.1 - 3.5   
 
2.Promyelocytes      0.5 - 5  
 
3. Myelocytes      5 - 23 
 
4. Metamyelocytes     7 - 27 
 
5. Band Forms      9 - 18 
 
6. Segmented Forms      4 - 28 
 
Erythroid series 
 
1. Proerythroblsats     0.1 - 1.1 
 
2. Basophiles      0.4 - 2.4 
 
3. Polychromatic     2 - 30 
        
4. Orthochromatic     2 - 10 
 
Lymphocytes      5 - 24 
 
Plasma Cells                                                             0 - 3.5   
 
Monocytes      0 - 0.6 
 
Macrophage      0 - 2 
 
Megakaryocytes     0 - 0.5 
 
RATIO 
 The M:E [myeloid:erythroid] ratio is based on a count of 200 – 500 
marrow cells.  In the normal adult the ratio is about 3 or 4:1. 
 
BONE MARROW TREPHINE BIOPSY [16,18] 
  A trephine biopsy is usually most easily carried out on the posterior 
superior iliac  spine, with the patient in the left or right lateral position with the 
knees drawn up. An  alternative  site is the ilium, just below the anterior superior 
iliac spine.  Various needle  designs are satisfactory including Jamshidi and Islam 
needles.  
 
A trephine biopsy and aspiration biopsy can be carried out through the 
same skin  incision but with the bone being entered at two different points, about 
1 cm apart.  Aspiration  is performed first.  It is easier to perform the least painful 
procedure first.  Local anesthesia must be adequate with particular attention being 
paid to infiltrating an adequate area of the periosteum.  In anxious patients 
sedation is useful.  The trephine should be inserted by to and  fro rotation through 
approximately 90 degree. The biopsy needle should be firmly fixed in the cortex 
of the bone before the trocar is removed.  Ideally, the biopsy should measure at 
least 20mm in length after processing. 
 
   Trephine biopsies can be carried out safely on patients with severe 
thrombocytopenia ,  but prolonged pressure is indicated to achieve primary 
haemostasis and reduce  bleeding to a minimum. 
 
               Bleeding problems are more likely in patients with coagulation defects 
and, if patients with severe liver disease or disseminated intravascular coagulation 
require a biopsy, the coagulation defect should be corrected, as far  as possible, 
before the procedure is undertaken. 
 
     Fix the specimen in 10 % formalin solutin buttered to pH 7.  Sections of 
marrow  should be stained as a routine by haematoxylin and eosin and by a 
reticulin impregnation  method.  H and E staining is excellent for demonstrating 
the cellularity and pattern of the marrow and for revealing pathological changes 
such as firbosis or the presence of granulomata or carcinoma. 
 
Diagnostic utility of bone marrow sampling in HIV positive 
patients[19] 
 
                Bone marrow sampling has diagnostic utility in HIV infected patients 
with pyrexia  without localising signs, pancytopenia, and staging/investigation of 
lymphoma; this test has little value in the investigation of afebrile patients with 
isolated thrombocytopenia, anaemia, or leucopenia as HIV is usually the 
underlying cause. Of 122 bone marrow samples taken to investigate pyrexia, 33 
(27%) revealed the cause on microscopy: unexpected lymphoma in seven (6%), 
mycobacteriosis in 25 (20%), and toxoplasmosis in one (1%). Marrow infiltration  
was confirmed in 11 of 38 bone marrow samples taken for staging/investigation 
of lymphoma/leukaemia. In afebrile patients, of 22 with pancytopenia, bone 
marrow samples showed HIV associated changes in 17 and specific diagnoses  in 
five. (Mycobacterial infection in three, haemophagocytic syndrome in one, and  
megaloblastic change due to vitamin B-12 deficiency in  one)  
 
 
                                      
 
 
 
                                         
PANCYTOPENIA 
                                                         
 
          Pancytopenia refers to a reduction in all three formed elements of the 
blood- erythrocytes, leukocytes and platelets. It is not a disease entity, but rather a 
triad of findings that may result  from a number of disease processes. 
 
  
Pathophysiology: 
 The mechanisms by which pancytopenia develops appear to be varied.  
1. Some conditions are associated with a decrease in haematopoietic cell 
production in bone marrow as a result of  
a) Destruction of marrow tissue by toxins (acellular or hypoplastic 
marrow) 
b) Replacement by abnormal or malignant tissue. 
c) Suppression of normal marrow growth and differentiation. 
 
2.  In other conditions the marrow may be normally cellular or even 
hypercellular, and no  abnormal cells may be present.  The mechanisms 
are 
 
a) Ineffective haematopoiesis with cell death in the marrow. 
b) Formation of defective cells that are rapidly removed from the 
circulation. 
c) Trapping of normal cells in hypertrophied and overactive 
reticuloendothelial system. 
d) Sequestration and/or destruction of cells by action of antibodies. 
  
CAUSES OF PANCYTOPENIA [8] 
 
Aplastic anaemia 
Subleukaemic acute leukaemia 
Administration of cytotoxic agents and antimetabolites 
Radiotherapy 
Myelodysplastic disorders 
Bone marrow infiltration or replacement: 
             Lymphoma,macroglobulinemia. 
             Multiple myeloma 
             Metastatic carcinoma in bone marrow 
             Myelofibrosis 
Hypersplenism 
Megaloblastosis-vitamin B 12 and folate deficiency 
Systemic lupus erythematosus 
Overwhelming infection 
Paroxysmal nocturnal hemoglobinuria 
Miscellaneous.  
 
Causes:[20] 
 The diverse causes of pancytopenia can also be classified as: 
 
 1.Pancytopenia with hypocellular bone marrow 
1.Acquired aplastic anaemia 
 
               2. Inherited aplastic anaemia 
 
3  Some Myelodyplastic syndrome 
 
                     4.Rare aleukaemic leukaemia [Acute myeloid leukaemia] 
 
5.Some acute lymphoid leukaemia. 
 
                    6.Some Lymphomas of bone marrow 
 
           II.Pancytopenia with cellular bone marrow 
 
A]Primary bone marrow diseases 
 
1.Myelodyplastic syndromes 
 
2.Paroxysmal nocturnal hemoglobinuria 
 
3.Myelofibrosis 
 
                                    4.Some aleukaemic leukaemia’s 
 
                                    5.Myelophthisis 
 
6.Bone marrow lymphoma 
 
7.Hairy cell leukaemia 
 
             B]Secondary to systemic diseases 
  
                         1.Systemic lupus Erythematosus 
 
                         2.Hypersplenism 
 
                        3.B12, folate deficiency 
 
                        4.Overwhelming infections 
 
                        5.Alcohol 
 
                        6.Brucellosis 
 
                        7.Sarcoidosis 
  
                        8.Tuberculosis 
 
                        9.Leishmaniasis 
 
              III.Hypocellular bone marrow ± Cytopenia 
 
 1.Q fever 
 
                               2  Legionnaires disease 
 
                               3. Anorexia nervosa 
 
                               4. Mycobacteria 
 
Clincial Features:[ 8,9,20] 
 The initial clinical picture in patients with pancytopenia varies 
widely.  The onset often is insidious.  Manifestations depend on the 
severity of the anaemia,  thrombocytopenia, or leukopenia. Sometimes 
pancytopenia is detected as an incidental feature in a patient  who has 
presented with symptoms of a disorder that is capable of depressing the 
levels of all cellular elements in the blood. The clinical features and 
simple laboratory finding reflect the underlying disease process and 
usually serve to reduce the number of possible diagnosis  quickly.  Thus, 
the  presence of splenomegaly calls attention to the possibility of 
leukaemia, myelofibrosis, congestive splenomegaly etc.  The presence of 
enlarged  lymph nodes further supports the possibilities of leukaemia, one 
of the lymphomas,  or lupus erythematosus.  On the other hand, lack of 
these signs and absence of  evidence of Vitamin B12 or folate deficiency 
should suggest multiple myeloma or  aplastic anaemia.  The presence of 
rouleaux on the blood smear or Bence Jones  protein in the Urine suggest 
myeloma.  Immature erythrocytes and leukocytes in the blood smear, 
(leukoerythroblstic blood picture) should lead the clinician to consider 
infiltrative disease in the bone marrow (e.g., metastatic carcinoma, 
leukaemia or myelofibrosis), except in the event of greatly accelerated 
blood formation and destruction, such as occurs in cases with frank 
haemolytic anaemia. 
 
 The anaemia usually is normochromic and normocytic, but 
occasionally,it  is mildly macrocytic.  The leukopenia usually results from 
a reduction in the absolute number of cells of the myeloid series and thus 
relative lymphocytosis is noted.  If, however, the reduction is sufficiently 
great, lymphocytopenia is found as well.  
 
Difficulties in diagnosis: 
 Difficulty arises when atypical features are encountered e.g: when 
a patient thought  to have aplastic anaemia has normally cellular or even 
hypercellular marrow. One explanation for such a contradictory findings is 
that the biopsy needle entered an area in which the bone marrow is 
regenerating after severedamage, such as after benzene intoxication or 
irradiation.  Another dilemma involves finding that several marrow 
aspirations are acellular in a patient thought to have leukaemia.  In most 
situations, a larger marrow sample obtained by biopsy will solve the 
problem.  With a few conditions, such as congestive splenomegaly the 
diagnosis is made largely by excluding the other possibilities.  Finally, in a 
few patients, no clearly defined syndrome can be recognized. 
 
Treatment: 
 The treatment of pancytopenia is dictated by the nature of the 
underlying disease. 
 
                             
APLASTIC ANAEMIA [8,9,20,21,22,23] 
 
Definition: 
          Aplastic anaemia is pancytopenia with bone marrow hypocellularity. 
 
Classification of aplastic anaemia[8,9,20] 
 
    ACQUIRED APLASTIC ANAEMIA 
 
a. Idiopathic aplastic anaemia  
 
b. Secondary aplastic anaemia 
 
Irradation  
 
            Drugs and chemicals 
 
Regular effects  
                         
                        Cytotoxic agents  
 
 Benzene  
 
Idiosyncratic reactions 
 
 Chloramphenicol 
 
 Nonsteroidal anti-inflammatory drugs 
 
 Antiepileptics 
 
 Gold 
 
 Other drugs and chemicals 
 
              Virus 
 
 Ebstein-barr virus ( infectious mononucleosis) 
 
 Hepatitis virus (non A, non  B, non C, non G hepatitis) 
 
 Parvo virus (transient aplastic crises, some pure red cell aplasia) 
 
 HIV (Acquired Immunodeficiency Syndrome) 
 
                 Immune diseases 
 
 Eosinophilic fasciitis  
 
 Hypoimmunoglobulinemia 
 
 Thymoma and thymic carcinoma 
 
 Graft-Versus-host disease in immunodeficiency 
 
Paroxysmal nocturnal hemoglobinuria 
 
Pregnancy 
 
 
           INHERITED APLASTIC ANAEMIA 
 
                        Fanconi’s anaemia 
 
 Dyskeratosis congenita  
 
 Shwachman – Diamond syndrome 
 
 Reticular dysgeneis 
 
 Amegakaryocytic thrombocytopenia 
 
 Familial aplastic anaemia’s 
 
 Preleukaemia (monosomy, etc.) 
 
                        Nonhaematologic syndromes (Down, Dubowrky, Sickle) 
  
 
Pathophysiology: 
 Bone marrow failure results from severe damage to the 
haematopoietic  cell compartment.Cells bearing the CD34 antigen, a marker of 
early haematopoietic cell,  are greatly diminished; and in functional studies, 
committed and  primitive progenitor cells  are virtually absent. Aplastic anaemia 
does not appear to result from defective stroma or  growth factor production. 
 
  Immune mediated injury 
             Blood and bone marrow cells of patients can suppress normal  
haematopoietic progenitor cell growth, and removal of T cells from aplastic 
anaemia bone marrow improves colony formation in vitro.  Increased numbers of 
activated  cytotoxic T cells are observed in aplastic anaemia patients and usually 
decline with  successful immuno-suppresive therapy.  Interferon and tumour 
necrosis factor induce Fas  expression on CD34 cells, leading to apoptotic cell 
death.  
. 
Clinical features 
History 
       Aplastic anaemia can appear with seeming abruptness or have a more 
insidious  onset.  Bleeding is the most common early symptom; a complaint of 
days to weeks of  easy bruising, oozing from the gums, nose bleeds, heavy 
menstrual flow and sometimes  petechiae will have been noticed.  Symptoms of 
anaemia are also frequent, including  lassitude, weakness, shortness of breath and 
a pounding sensation in the ears.  Infection is  an unusual first symptom in 
aplastic anaemia.  A striking feature of aplastic anaemia is  the restriction of 
symptoms to the haematologic system. History of drug use,  chemical exposure 
and preceding viral illness must often be elicited with repeated questioning.    
 
Physical examination 
 Pallor of the skin and mucous membranes is common.  Petechiae and 
ecchymoses  are often present, and retinal haemorrhages may be present.  
Infection on presentation is  unusual but may be present if the patient has been 
symptomatic for few weeks.  Lymphadenopathy and splenomegaly are highly 
atypical of aplastic anaemia.  Café au lait spots and short stature suggest 
Fanconi’s anaemia , peculiar nails  Dyskeratosis congenita. 
 Laboratory studies 
Blood 
 The smear shows erythrocytes and a paucity of platelets and granulocytes.  
Reticulocytes are absent or few, and lymphocyte numbers may be normal or 
reduced.  
 
Bone marrow 
 The bone marrow is usually readily aspirated but appears dilute on smear, 
and the  fatty biopsy specimen may be grossly pale on withdrawal.  The biopsy is 
superior for  dertermination of cellularity and shows mainly fat under the 
microscope, with  haematopoietic cells occupying, by definition, <25% of the 
marrow space. The  correlation between marrow cellularity and disease severity is 
imperfect.  
 
Ancillary studies 
 Chromosome breakage studies of peripheral blood  using 
diepoxybutane[DEB] or  mitomycin C should be performed on children to 
exclude Fanconi’s  anaemia.Chromosomal studies of bone marrow cells are often 
revealing in  myelodysplastic syndrome and should be negative in typical aplastic 
anaemia.Flow  cytometric studies have replaced the Hams test for the diagnosis of 
PNH.Serological  studies may show evidence of viral infection,especially Ebstein 
Barr virus and HIV.Post  hepatitis aplastic anaemia is typically seronegative. 
 
PROGNOSIS 
              The major prognostic determinant is the blood count. Severe disease is 
defined  by the presence of two or three parameters, absolute neutophil count 
<500/ cu.mm,   platelet count <20000 /cu.mm, and corrected reticulocytes count < 
1%.  Survival of  patients who fulfill these criterial is about 20% at one year after 
diagnosis: patients with  very severe disease, defined by an  absolute neutrophil 
count <200/ cu.mm  do even  more poorly. 
 
Treatment 
Treatment includes therapies that reverse the underlying marrow failure 
and  supportive care of the pancytopenic patient.  Severe acquired aplastic 
anaemia can be  cured by replacement of the absent haematopoietic cells by stem 
cell transplant, or  ameliorated by suppression of the immune system to allow 
recovery of the patients  residual bone marrow function.  Haematopoietic growth 
factors have limited usefulness  and glucocorticoids are of no value.  Suspect 
exposures to drugs or chemicals should be  discontinued. 
 
Bone marrow transplation 
 This is the best therapy for the young patient with a fully histocompatible 
sibling  donor.  For allogenic transplant from fully matches siblings, long-term 
survival rates for  children are about 80%.  Transplant morbidity and mortality are 
increased among adults,  due mainly to the increased rate of chronic graft-versus-
host disease and serious infections.   Survival using alternative donors is about 
half that of conventional sibling transplants.  
 
Immunosuppression 
               Used alone, antilymphocyte globulin (ALG) or antithymocyte globulin, 
(ATG) induces  haematologic recovery in about 50% of patients.  The addition of 
cyclosporine to either ALG or  ATG has further increased response rates to about 
70% to 80%. Combined treatement is now  standard for patients with severe 
disease. 
 
 Horse ATG is given at 40mg/kg per day for four days, rabbit ALG is 
administered  at 3.5 mg/kg per day for five days.  Most patients are given 
methylprednisolone, 1 mg/kg  per day for two weeks, to ameliorate the immune 
consequences of heterologous protein  infusion.  Cyclosporine is administered 
orally at an initial dose of 12 mg/kg per day in  adults, with subsequent 
adjustment according to blood levels obtained every two weeks.  
 
Other therapies 
   The effectiveness of androgen therapy has not been verified in controlled 
trials,  but occasional patients will respond.  For patients with moderate disease or 
those with  severe pancytopenia who have failed immunosuppression, a 3 to 4 
months trail is  appropriate.  Haematopoietic growth factors, G-CSF, GM-CSF 
and interleukin-3, are not  recommended as initial therapy for severe aplastic 
anaemia.  
 
Supportive care 
 Both platelet and erythrocyte numbers can be maintained by transfusion.  
Any  rational regimen of prophylaxis requires transfusions once or twice weekly 
in order to maintain the platelet count >10,000 . Menstruation should be 
suppressed by oral estrogen.  Red blood cells should be transfused to maintain a 
normal level of activity, usually at a hemoglobin value of 70 g/L (90 g/L if there 
is underlying cardiac or pulmonary disease), a regimen of 2 units every 2 weeks 
will replace normal losses in patient without a functioning bone marrow. 
                           
                             HYPERSPLENISM [8,9,20] 
Definition 
 It has been known for many years that certain patients with splenomegaly  
secondary to a number of disorders develop neutropenia, anaemia, or 
thrombocytopenia,  either singly or in combination and that splenectomy results in 
varying degrees of  improvement in the peripheral blood picture, even to normal.  
The fact that the peripheral  blood picture is corrected by splenectomy led to the 
concept of hypersplenism.  
 
Etiology 
 Secondary 
 
  Portal hypertension with congestive splenomegaly 
   
Lymphomas 
   
Sarcoidosis 
   
Felty’s syndrome 
   
Lipid storage disease – Gauchers’s disease 
   
Kala azar, Chronic Malaria, tropical splenomegaly 
 
Bacterial infections – tuberculous, brucellosis, bacterial 
endocarditis,  
 
Thalassemia 
 
Chronic Lymphatic leukaemia 
 
Myelofibrosis 
 
Hairy cell leukaemia 
 
Primary ( idiopathic) 
 
Mechanism of hypersplenism 
 The processes involved in depression of the red cell count is pooling of 
red cells  within the enlarged spleen.  Studies with radio-isotope labeled red cells 
indicate that  passive pooling of red cells in the spleen has a greater impact on 
lowering the red cell  count in the blood than accelerated destruction of entrapped 
red cells, although the latter  can occur to some extent in some instances. 
 
Diagnostic criteria of hypersplenism[8,24] 
1. Anaemia, leukopenia or thrombocytopenia, either singly or in 
combination 
 
2. Cellular or hyperplastic bone marrow 
 
            3     Splenomegaly 
 
4.    Significant improvement in the peripheral blood picture following 
splenectomy. 
 
         In many cases of hypersplenism, the cause of the splenomegaly is 
suggested by the presence of manifestations of the underlying disease, e.g 
portal  hypertension or lymphoma and is confirmed by appropriate 
investigation.  
 
  Treatment 
 Splenectomy produces partial or complete recovery of the 
abnormal blood  picture in otherwise uncomplicatied cases.  When the 
effect of hypersplenism  is not sufficient to cause symptoms, splenectomy 
offers no benefit to the patient.   Splenectomy is indicated when 
significant problems  are caused by the sole or the  additional effect of 
hypersplenim in reducing the count of blood cells, usually anaemia of 
sufficient severity  to cause symptoms, neutropenia predisposing to 
infectious, or thrombocytopenia causing spontaneous bleeding. 
     MEGALOBLASTIC  ANAEMIA 
[8,9,26] 
 
            The megaloblastic anaemia’s are disorders caused by impaired DNA 
synthesis.  Cells primarily affected are those having relatively rapid 
turnover,especially haematopoietic precursors and gastrointestinal epithelial cells.  
Cell division is sluggish, but cytoplasmic development progresses normally, so 
megaloblastic cells tend to be large, with an increased ratio of RNA to DNA 
.Megaloblastic erythroid progenitors tend to be destroyed in the marrow 
(ineffective erythropoiesis) 
 
Classification of the megaloblastic anaemia’s 
Cobalamine deficiency 
 
I  Inadequate intake - Vegetarians 
 
II   Malabsorption 
 
A. Defective release of Cobalamine from food 
 
1. Gastric achlorhydria 
 
2. Partial gastrectomy 
 
3. Drugs that block acid secretion 
 
 
 
B   Inadequate production of intrinsic factor (IF) 
 
1. Pernicious anaemia 
 
2. Total Gastrectromy 
 
3. Congenital absence or functional abnormality of IF (rare) 
 
 
 
C  Disorders of terminal ileum 
 
1. Tropical sprue 
 
2. Non-tropical sprue 
 
3. Regional enteritis 
 
4. Intestinal resection 
 
5. Neoplasma and granulomatous disorder (rare) 
 
      
    D  Competition for Cobalamine 
 
1. Fish Tapeworm (Diphyllobothrium latum) 
 
2. Bacteria : “blind loop” syndrome 
 
 
      E   .Drugs: p-amino salicyclic acid, colchicines, neomycin  
 
 
III  Others 
 
A.  Nitrous oxide 
 
      B.   Congential enzyme defect 
 
 
 
Folic acid deficiency 
 
 
I Inadequate intake: Unbalanced diet (common in alcoholics, teenagers) 
 
 
II Increased requirements 
 
A. Pregnancy 
 
B. Infancy 
 
C. Malignancy 
 
D. Increased haematopoiesis 
 
E. Chronic exfoliative skin disorders 
 
F. Haemodialysis 
 
 
III  Malabsorption 
 
 A. Tropical sprue 
 
B  Non-tropical sprue 
 
C.Drugs: Phenytoin, barbiturate,(?) ethanol 
 
 
IV  Impaired metabolism 
 
 
A. Inhibitors of dihydrofolate reductase: methotrexate, pyrimethamine,         
         
triamterene, pentamidine. 
 
B. Alcohol 
 
 
Other causes 
 
 
I          Drugs that impair DNA metabolism 
 
A. Purine antagonists: 6-mercaptopurine , azathioprine, etc 
 
B. Pyrimidine antagonists:5 – flurouracil, cytosine arabinoside etc. 
 
C. Others: Procarbazine, hydroxyurea, acyclovir, zidovudin 
 
 
II  Metabolic disorders 
 
A. Hereditary orotic aciduria 
 
B. Lesch-Nyhan syndrome 
 
 
III  Megaloblstic anaemia of unknown eitiology 
 
A. Refractory megaloblastic anaemia 
 
B. Di Guglielmos syndrome 
 
C. Congenital dyserythropoietic anaemia 
 
 
Clinical features 
 
1.Cobalamine deficiency 
 The clinical features of cobalamine deficiency involve the blood, the  
gastrointestinal tract, and the nervous system. The haematologic manifestations 
are almost entirely the result of anaemia,  although very rarely purpura may 
appear, due to thrombocytopenia.  Symptoms of anaemia may include weakness, 
light-headedness, vertigo and tinnitus, as well as palpitation, angina and the 
symptoms of congestive failure.  On examination, the patient  is pale, with slight 
icterus of skin and eyes.  The gastrointestinal manifestation are sore  tongue, 
which on inspection will be smooth and beefy red, anorexia with moderate  
weight loss, possibly accompanied by diarrhoea.  The neurologic manifestations 
include  numbness, paresthesia in the extremities, weakness and ataxia , due to 
demyelination,  followed by axonal degeneration of peripheral nerves, the spinal 
cord and the cerebrum  itself. 
 
2.Folate deficiency 
 Patients with folic acid deficiency are more often malnourished than those 
with cobalamine deficiency.  The haematologic and gastrointestinal 
manifestations are the same as those of cobalamine deficiency.  However, in 
contrast to cobalamine deficiency,neurologic abnormalities do not occur. 
 
Diagnosis 
 
 The findings of significant macrocytosis (MCV > 100 fl) suggests the 
presence of a megaloblastic anaemia.  The reticulocyte count may also be 
decreased particularly in severely anaemic patient.  The blood smear demonstrates 
marked anisocytosis and poikilocytosis, together with macrovalocytes.  In the 
white blood cell series, the neutrophils show hypersegmentation of the nucleus.  
Bizarre, misshapen platelets are also observed.   
 
 The bone marrow is hypercellular with a decreased myeloid/erythroid 
ratio.  RBC  precursors are abnormally large and have nuclei that appear much 
less mature than would be expected from the development of the cytoplasm.  The 
nuclear chromatin is more dispersed than expected, and it condenses in a peculiar 
fenestrated pattern.  Granulocyte precursors are also affected, many being larger 
than normal, including meta-myelocytes.   Megakaryocytes are decreased and 
show abnormal morphology.Enhanced intramedullary  destruction of 
erythroblasts results in an increase in unconjugated bilirubin and lactic acid  
dehydrogenase in plasma.  Once cobalamine deficiency has been established, its 
pathogenesis  can be delineated by means of Schilling test.  
 
 
Treatment 
 
Cobalamine deficiency 
           Apart from specific therapy related to the underlying disorder, the mainstay 
of treatment  for cobalamine deficiency is replacement therapy.Parental treatment 
begins with  1000micro g cobalamine daily for 1 week followed by weekly for 
eight weeks and every  month later  for the rest of patient’s life.  
 
Folate deficiency 
  As for cobalamine deficiency, folate deficiency is treated by replacement  
therapy.  The usual dose of folate is 1 mg/d by mouth, but higher doses ( upto 5 
mg/d )  may be required for folate deficiency due to malabsorption.  
 
PATIENTS AND METHODS 
 
Study Setting: 
The study was carried out in subjects attending the Christian Medical College  
Hospital,Vellore, a tertiary care teaching hospital.  
. 
Study Design: 
Cross sectional survey  of patients with pancytopenia. 
 
Subjects: 
Consecutive patients with a diagnosis of pancytopenia ,defined as [27] 
 
                                              Hemoglobin < 10g/dl,and 
                                                
                                              Total leucocyte count < 4000/cu.mm,and 
 
                                              Platelet count < 1,00,000/cu.mm. 
 
Patients were recruited from inpatient as well as outpatient departments of 
General Medicine and  Haematology . All newly detected cases of pancytopenia  
were  taken up for further  evaluation.Patients who had  normal blood counts at  
first visit and subsequently had   pancytopenia [secondary to 
drugs,radiotherapy.etc] were not included in the study. 
 
Inclusion criteria: 
All newly detected adult  patients[age  >12 years] with pancytopenia were 
included in the study. 
 
Exclusion criteria: 
1. Patients with normal blood counts at  first visit and  subsequently manifesting 
pancytopenia[secondary to drugs,radiotherapy.etc] 
 
2. Age <12 years. 
 Subject enrollment: 
The list of patients fulfilling the inclusion criteria  were obtained daily from the  
Department of clinical pathology [Hospital numbers,Name and Age] and  then 
traced for  further evaluation and diagnostic work up.OPD patients who could not 
be seen  the same day were followed up during subsequent visits. 
 
Evaluation: 
Cases enrolled  were evaluated in detail by history,physical examination  and  
relevant labarotary investigations,and the details entered in a proforma. 
[Appendix] Bone marrow aspiration and  biopsy were planned to be undertaken in 
all cases. Patients with pancytopenia on whom bone  marrow  were not done were 
also included in the study. 
 
Procedures: 
Bone marrow aspiration and biopsy were done after an informed consent was  
obtained.Patients were premedicated with pethidine and phenargan.Local 
infiltration  anaesthesia [2% xylocaine] was used and sterile precautions were 
observed.With a boring  movement,bone marrow needle was passed 
perpendicularly into the cavity of ilium at  posterior superior iliac spine.When the 
bone has been penetrated ,with a 5 ml syringe 0.2-0.3ml of  marrow was 
aspirated.The aspirate was transferred to a set of slides and  smeared.Slides were 
stained with Romanovsky dyes.Trephine biopsy was done through the same 
site.The trocar was removed after biopsy needle was fixed in the cortex  and the 
needle was pushed further into the marrow.The needle was removed and the 
specimen transferred to 10% formalin solution.A tincture benzoin seal 
applied.Section of marrow  was stained by Haematoxylin and eosin stain.    
 

Diagnostic criteria for etiological conditions: 
 
1.APLASTIC ANAEMIA:Presence of pancytopenia with a fatty,empty bone 
marrow and haematopoietic cells occupying, by definition, <25% of the marrow 
space.[8,9,20] 
 
2. HYPERSPLENISM: A.  Anaemia, leukopenia  and thrombocytopenia. 
    
                                      B.   Cellular or hyperplastic bone marrow 
                                      C.    Splenomegaly 
 
 In many cases of hypersplenism, the cause of the splenomegaly was suggested by 
the  presence of manifestations of the underlying disease, e.g portal hypertension 
which was  confirmed by appropriate investigation.In patients  whom bone 
marrow could not be  carried out ,indirect evidence of bone marrow functioning 
was obtained by reticulocyte  response. 
 
3. SUBLEUKAEMIC LEUKAEMIA:Depressed leucocyte counts with >30% of 
the bone marrow  consisting of blast cells. 
 
4.MEGALOBLASTIC ANAEMIA:Bone marrow showing  characteristic 
megaloblastic erythroid and granulocytic precursors and /or documented low 
levels of vitamin B12,folic acid. 
 
5.MYELODYSPLASTIC SYNDROME:Bone marrow revealing 
dyserythropoietic  changes (especially nuclear abnormalities ) and ringed 
sideroblasts in the erythroid  lineage; hypogranulation and hyposegmentation in 
granulocytic precursors, with an increase in myeloblasts ; and megakaryocytes 
showing reduced number of disorganized nuclei. 
 
6.SYSTEMIC LUPUS ERYTHEMATOSUS:Presence of  atleast  4 of the 11 
criteria. Malar rash,discoid rash,serositis,oral ulcers,photosensitivity,non erosive 
arthritis,renal  abnormalities,neurological manifestation,presence of 
autoantibodies,immunological  phenomenon and haematological manifestations.  
 
7. INFILTRATIVE DISORDERS:Bone marrow examination [Documented 
evidence of  granuloma,lymphoma,myeloma cells .etc.] 
 
8.SEPSIS:Documented source of infection with evidence of bone marrow  
suppression/haemophagocytic syndrome. 
 
The cause of pancytopenia was classified  as “unknown” if  it was not evident 
after  extensive investigations or incomplete diagnostic work up of OPD patients 
as they were  lost to follow up after the first visit.  
 
Statistical methods: 
Data entry was done using the software package ,SPSS 11. Descriptive statistics 
[distribution of age,sex,etc]  were analysed  using SPSS. Odds ratio,sensitivity 
and specificity   were calculated using EPI INFO software and a p value less than 
0.05 was considered  statistically significant. 
 
 
   
 
 
  
                              
 
 
 
 
                                        RESULTS 
 
One hundred and fifty [150] consecutive patients with pancytopenia were studied   
during the period  Jan 2005 to Jun 2005 at Christian Medical College  
Hospital,Vellore. The following data were recorded and analysed. 
 
AGE DISTRIBUTION 
                      TABLE SHOWING THE AGE DISTRIBUTION  
Age group in 
years 
Number of cases Percent 
 
13-20 
 
17 
 
11.3 
 
21-30 
 
29 
 
19.3 
 
31-40 
 
34 
 
22.7 
 
41-50 
 
33 
 
22.0 
 
51-60 
 
14 
 
9.3 
 
61-70 
 
19 
 
12.7 
 
71-80 
 
4 
 
2.7 
 
Mean age:40.34  years,SD:15.952,Median:40, Range:13-77 (64) 
 
In the present study,most of the patients were in the third [19.3 ],fourth[22.7] and 
fifth  decade [22.0].The mean age is 40.34. 
 
SEX DISTRIBUTION: 
 
Sex 
 
Frequency Percent 
Male 
 
93 62.0 
 
Female 
57 38.0 
 
Total 
150 100.0 
 
 
In the present study the male:female ratio was 1.62:1.  
CLINICAL PROFILE: 
 
     TABLE SHOWING SYMPTOMS AND SIGNS AT PRESENTATION 
 
Clinical profile FREQUE
NCY 
PERCENTAG
E 
Easy fatiguability 
 
119 79.3 
Breathlessness 
 
20 13.4 
Fever 
 
50 33.3 
Bleeding manifestations 
 
48 32.0 
Pallor 
 
150 100.0 
Icterus 
 
16 10.7 
Lymphadenopathy 
 
8 5.3 
Hepatomegaly 
 
18 12.0 
Splenomegaly 
 
42 28.0 
Peripheral neuropathy 
 
7 4.7 
 
 The most common presenting symptoms  were that of easy fatiguability 
[79.3%]  followed by  fever [33.3%] and bleeding manifestations 
[32.%].Examination wise pallor  was a universal finding  followed by 
splenomegaly [28%] and hepatomegaly. [12%] .                              
 
                                    HAEMATOLOGICAL PARAMETERS 
 
 Hemoglobin 
g/dl 
Total WBC  
count 
cells/cu.mm 
Platelet count 
cells/cu.mm 
Mean 6.963 2378.00 34926.67 
Median 7.400 2350.00 24000.00 
Std. Deviation 2.0460 781.916 29983.686 
Range 2 – 10 500 - 4000 1000 – 100000 
 
 
In the present study the mean hemoglobin percentage was 6.96 g/dl, total WBC 
count 2378 cells/cu.mm  and platelet count was 34926 cells/cumm. 
 
  Distribution of Hemoglobin in patients with 
Pancytopenia 
 
HEMOGLOBIN 
CATEGORY     G/DL 
 
Frequency 
 
Percent 
1-4 
 
17 11.3 
4.1-7 
 
47 31.3 
7.1-10 86 57.3 
 
Total 150 100.0 
 
 
The hemoglobin varied from 2.0 to 10 g/dl.  Majority of the patients had 
hemoglobin ranging from 7.1 to 10 g/dl .[57.3%] 94% of the patients who had 
Hemoglobin<4g/dl  had symptoms of easy fatiguability,in  contrast with 32.3% of 
patients with hemoglobin in the range 7.1-10 g/dl. 
 
 
H e m o g lo b in  c a te g o ry
  7 .1 -1 0        
    5 7 .3  %  
   4 .1 -7  
    3 2 .3  %  
     < 4   
  1 1 .3  %  
 
 
 
Range of total WBC count in patients with 
pancytopenia 
 
  
 
 
 
 
 
 
 
 
The total WBC count ranged from 400 cells/cu.mm to 3900 cells /cu.mm.Majority 
of the patients were in the range between 2001-3000 cells/cu.mm.[42.7%] 
TOTAL 
Total WBC Count   
(cells/cu.mm) 
Frequency Percent 
Upto 1000 
 
6 4.0 
1001-2000 
 
45 30.0 
2001-3000 
 
64 42.7 
3001-4000 
 
35 23.3 
Total 
 
150 100.0 
 
WBC count category
3001-4000 
    23.3 % 
2001-3000 
    42.7 % 
1001-2000 
     30 % 
Upto 1000 
      4 % 
 
         Range of platelet count in patients with 
pancytopenia 
 
Platelet count cells/cu.mm
 
Frequency Percent 
Upto 20000 
 
68 45.3 
20001-50000 
 
44 29.3 
50001-100000 38 
 
25.3 
Total 150 100.0 
 
Platelet count category  
    
    50001-100000  25.3 %  
   
     20001-50000 -29.3 % 
    
    Upto 20000  45.3%  
 
In the present study,platelet count ranged from 1000 to 1 
lakh/cu.mm.Majority of the patients were in the range between 1000-
20000.[45.3%] 35 [73%]of the 48 patients who presented with bleeding 
manifestations had platelet count less than  20000. 
BONE MARROW CELLULARITY 
In the present study,majority of the patients had a hypocellular marrow [44 
%].Bone marrow examination could not be carried out in 31[20.7%] participants 
due to various reasons.[Lack of consent-17,obvious diagnosis on noninvasive 
testing-low B12 levels-1, evidence of  portal hypertension with splenomegaly-19, 
blasts on blood picture-2] 
 
 
Frequency Percent 
 Hypocellular 
 
66 44.0 
Hypercellular 
 
53 35.3 
Not done 31 20.7 
 
Total 
 
150 100 
 
Bone marrow cellularity
  Missing 
   20.7 % 
Hypercellular 
    35.3 % 
Hypocellular 
 
       44% 
 
 
                          ETIOLOGY OF  PANCYTOPENIA 
 
   Frequency Percent 
  
Aplastic anaemia 
 
 
41 
 
27.3 
  
Myelodysplastic syndrome 
 
 
 
14 
 
9.3 
  
Subleukaemic leukaemia 
 
 
 
19 
 
12.6 
  
Hypersplenism 
 
 
38 
 
25.3 
  
Megaloblastic anaemia 
 
 
8 
 
5.3 
  
Infiltrative disorders 
 
13 
 
8.7 
  
Sepsis 
 
2 
 
1.3 
  
Systemic lupus erythematosus
 
 
2 
 
1.3 
  
Unknown 
 
 
13 
 
8.7 
 
 
Infiltrative disorders included tuberculosis, nonhodgkins lymphoma, multiple 
myeloma and cryptococcosis. The most common cause of  pancytopenia in this 
study is aplastic anaemia[27.3%] followed by hypersplenism[25.3%] and 
subleukaemic leukaemia[12.6%]. Rare causes include sepsis[1.3%] and systemic 
lupus erythematosus.[1.3%] 
 
PANCYTOPENIA WITH APLASTIC ANAEMIA 
In  the present  study,most common cause of aplastic anaemia was 
idiopathic[92.7%]. There were 3 cases of drug induced aplastic 
anaemia.[Azothioprine,busulfan and imatinib]. 
 
ETIOLOGY 
 
FREQUENCY (%) 
N=41 
IDIOPATHIC 
 
38  (92.7) 
 
DRUG INDUCED 
3  (7.3) 
 
65 % [27/41]of the patients were in the third ,fourth and fifth decade of life. 
Male:Female ratio was 1.73.(Male –26  Female –15) 
 
  
 TABLE SHOWING THE AGE DISTRIBUTION IN PATIENTS WITH 
 
                                        APLASTIC ANAEMIA 
 
 
 
Mean age-37.93 years,Median-37, Standard deviation-16.041, Range-15-75. 
 
 
  TABLE SHOWING SYMPTOMS AND SIGNS OF PATIENTS WITH 
APLASTIC ANAEMIA  
 
 
Clinical profile 
 
FREQUE
NCY 
 
PERCENTAG
E 
 
Age category Frequency (%) 
N = 41 
 
13-20 
 
 
6 (15) 
 
21-30 
 
 
10 (24) 
 
31-40 
 
 
7 (17) 
 
41-50 
 
 
10 (24) 
 
51-60 
 
 
3 (7) 
 
61-70 
 
 
4 (10) 
 
71-80 
 
 
1 (3) 
 
Easy fatiguability 
 
 
35 
 
85 
 
Breathlessness 
 
 
6 
 
14.6 
 
Fever 
 
 
11 
 
26.8 
 
Bleeding manifestations 
 
 
28 
 
68.2 
 
Pallor 
 
 
41 
 
100.0 
 
The most common presenting symptoms  were that of easy fatiguability [85 %] 
followed by  bleeding manifestations [68.2.%] and fever [26.8 %] and 
examination wise  none of the patients had hepatosplenomegaly. Symptomatic 
thrombocytopenia was more common in the aplastic anaemia group [68.2%] as 
compared overall.[32%] 
 
HAEMATOLOGICAL PARAMETERS IN PATIENTS WITH 
APLASTIC ANAEMIA 
 
  
Hb g/dl 
 
 
Total WBC 
cells/ cu.mm 
 
Platelets 
cells/cu.mm 
 
 
Mean 
 
 
6.495 
 
2446.34 
 
8365.85 
 
Median 
 
6.800 
 
 
2400.00 
 
7000.00 
 
Std. Deviation
 
2.0118 
 
670.111 
 
 
5252.409 
 
Range 
 
2 – 9.9 
 
200 – 3900 
 
1000 – 23000 
 
 
The mean platelet count in the aplastic anaemia group was only 8365 cells/cu.mm 
as compared with overall mean of 34296 cells/cu.mm. 
 
MCV IN PATIENTS WITH APLASTIC ANAEMIA 
 
Mean 
 
90.941 
 
 
Median 
 
88.400 
 
 
 
Std. Deviation 
 
Range 
 
 
9.0339 
 
74.8-112.1 
 
BLOOD PICTURE IN PATIENTS 
WITH APLASTIC ANAEMIA   
 
 
 
 
FREQUENCY
N = 40 
 
Normocytic 
normochromic 
 
 
20 (48.7 %) 
 
Microcytic 
Hypochromic 
 
 
 
8 ( 19.5 %) 
 
Macrocytosis 
 
 
12 (29.2 %) 
 
The most common  blood picture in patients with aplastic anaemia was 
normocytic normochromic [48.7%].  
All patients[41] with aplastic anaemia had a hypocellular marrow.  
  
 
 
Low-power,H&E stained bone marrow biopsy from a patient with severe 
aplastic anaemia 
 
  
 
                                                    HYPERSPLENISM 
 
                     The most common cause of hypersplenism is portal hypertension 
.[71%] Other causes  included kala-azar,hemolytic anaemia,malaria and hairy cell 
leukaemia.The cause of  hypersplenism was considered idiopathic in 5 patients in 
whom no cause was found after  extensive investigations. 
 
 
ETIOLOGY 
 
FREQUENCY (%) 
N =38 
 
PORTAL 
HYPERTENSION 
 
27  (71) 
 
IDIOPATHIC 
 
 
5  (13) 
 
KALA AZAR 
 
 
2   (5) 
 
HEMOLYTIC 
ANAEMIA 
 
2   (5) 
 
MALARIA 
 
 
HAIRY CELL 
LEUKAEMIA 
 
 
1   (3) 
 
 
1 (3) 
 
 
 
 
 
 
 
 
TABLE SHOWING THE AGE DISTRIBUTION IN PATIENTS WITH 
HYPERSPLENISM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean age-42.71 years, Median-40 , Standard deviation-16.050, Range- 15-72. 
Male:Female ratio is 1.71:1. [Male-24, Female-14] 
 
Age category Frequency (%) 
N = 38 
 
13-20 
 
 
4 (10) 
 
21-30 
 
 
5 (13) 
 
31-40 
 
 
11 (29) 
 
41-50 
 
 
6 (16) 
 
51-60 
 
 
6 (16) 
 
61-70 
 
 
5 (13) 
 
71-80 
 
 
1 (3) 
  TABLE SHOWING SYMPTOMS AND SIGNS IN PATIENTS WITH 
HYPERSPLENISM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Easy fatiguability 
was the most 
common symptom [71%]  and splenomegaly was a universal finding on 
examination in patients with hypersplenism. 
    
HAEMATOLOGICAL PARAMETERS IN PATIENTS WITH 
HYPERSPLENISM 
  
Hb g/dl 
 
 
TC cells/ cu.mm 
 
Platelets 
cells/cu.mm 
 
Clinical profile 
 
FREQUE
NCY 
 
PERCENTAG
E 
 
 
Easy fatiguability 
 
 
27 
 
71 
 
Breathlessness 
 
 
2 
 
5 
 
Fever 
 
 
8 
 
21 
 
Bleeding manifestations 
 
 
9 
 
24 
 
Pallor 
 
 
38 
 
100.0 
 
Icterus 
 
 
10 
 
26 
 
Hepatomegaly 
 
 
6 
 
16 
 
Splenomegaly 
 
 
38 
 
100 
 
 
Mean 
 
 
7.174 
 
2342.11 
 
51078.95 
 
Median 
 
 
7.550 
 
2350.00 
 
46500.00 
 
Std. Deviation 
 
 
2.1355 
 
720.222 
 
23284.819 
 
Range 
 
3.1 – 10 
 
1000 – 3800 
 
9000 - 99000 
MCV  IN PATIENTS WITH HYPERSPLENISM 
 
Mean 
 
80.243 
 
 
Median 
 
79.100 
 
 
 
Std. Deviation 
 
 
12.495 
 
 
Range 
 
51.6 – 106.7 
 
 
BLOOD PICTURE IN PATIENTS WITH HYPERSPLENISM 
 
 
 
 
FREQUENCY 
N = 27 
 
Normocytic 
normochromic 
 
 
5 (18.5 %) 
 
Microcytic 
Hypochromic 
 
 
 
17 ( 63 %) 
 
Macrocytosis 
 
 
5 (18.5 %) 
 
The most common blood picture in patients with hypersplenism was microcytic 
hypochromic [63%] probably secondary to gastrointestinal blood loss due to 
portal hypertension. All the patients [19] on whom bone marrow was done 
showed a hypercellular picture. 
 
 
          HYPERSPLENISM AND HBSAG INFECTION 
   6    3
  29   83
HBSAG  PRESENT  ABSENT
  
     HYPERSLENISM 
 POSITIVE 
NEGATIVE  
 
 
Fisher’s exact  p value:0.017     
Odds ratio[OR]=5.7. [95% CI 1.3,24.4]   p=0.018  
Patients with hypersplenism were more likely to be having  chronic HBV 
infection.[OR=5.7. 95% CI 1.3,24.4.   p=0.018] 
 
 
 
 
HYPERSPLENISM AND HCV INFECTION 
   3 2
  31   82
  HCV  PRESENT  ABSENT
  
     HYPERSLENISM 
 POSITIVE 
NEGATIVE 
 
  Fisher’s exact p value:0.143 
  Odds ratio[OR]=3.97  [95% CI 0.6-24.8]  p=0.141 
  Patients with hypersplenism were more likely to be having HCV infection.  
 
                                        INFILTRATIVE DISORDERS 
 
In the present study,tuberculosis [54 %] is the most common infiltrative disorder  
responsible for pancytopenia..Other causes included non hodgkins lymphoma[31 
%], multiple myeloma and cryptococcosis. 
 
ETIOLOGY 
 
FREQUENCY (%) 
N = 13 
 
 
TUBERCULOSIS 7   (54) 
 
NON HODGKINS 
LYMPHOMA 
 
4   (31) 
 
MULTIPLE 
MYELOMA 
 
1   (7.5) 
 
CRYPTOCOCCOSIS 
 
1  (7.5) 
 
 
 
 
         INFILTRATIVE DISORDERS AND HIV INFECTION 
   6   5
7 104
  HIV  PRESENT  ABSENT
  
 INFILTRATIVE DISORDER 
 POSITIVE 
NEGATIVE 
 
HIV testing not done in 28 patients  
Fisher’s exact  p value[0.0000] 
Odds ratio[OR]=18.95  [95% CI 4.3,73.2]   p=0.000 
Patients with bone marrow infiltrative disorders were much more likely to be  
HIV infected.  
[ OR=18.95.  95% CI 4.3,73.2.  p=0.000] 
 
HIV INFECTION AND PANCYTOPENIA 
 
11 of the 122 patients who were tested for HIV were positive.[7.3%] Etiological 
workup in these patients revealed tuberculosis in 45.4% of the individuals 
[5/11].There was one case of disseminated cryptococcosis. Other 5 causes of 
pancytopenia were attributed to HIV infection per se after excluding drug induced 
aplasia,opportunistic infections and malignancy. 
HIV 
 
Frequency Percent 
Positive 11 7.3 
 
Negative 
 
111 74.0 
Total 
 
122 81.3 
 
HIV testing not done in 28 patients. 
ETIOLOGY OF PANCYTOPENIA IN HIV INFECTED 
INDIVIDUALS 
ETIOLOGY 
 
FREQUENCY (%) 
N = 11 
 
TUBERCULOSIS 
 
5  (45.5) 
 
IDIOPATHIC 
 
5  (45.5) 
 
CRYPTOCOCCOSIS 
 
1   (9) 
TUBERCULOSIS AND HIV INFECTION 
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  HIV  PRESENT  ABSENT
   
    TUBERCULOSIS 
 POSITIVE 
NEGATIVE 
  
 
 
   Fisher’s exact  p value[0.0000] 
   Odds ratio[OR]=30.95  [95% CI 5.8,156.3]   p=0.000                                                                               
  
Patients with tuberculosis were much more likely to be  HIV infected.  
 [ OR=30.95.  95% CI 45.8,156.3.  p=0.000] 
          SUBLEUKAEMIC LEUKAEMIA 
 
ETIOLOGY 
 
FREQUENCY (%) 
N = 19 
AML 
 
15  (79) 
 
ALL 
 
4   (21) 
 
Subleukaemic leukaemia was surprisingly the third most common cause of 
pancytopenia.15  of them were categorized as having AML[78.9%] and the rest as 
ALL[21.1%]. 
 
TABLE SHOWING THE AGE 
DISTRIBUTION IN PATIENTS 
WITH SUBLEUKAEMIC LEUKAEMIA 
 
 
 
 
 
 
 
 
 
 
 
 
Age category Frequency (%) 
N = 19 
 
13-20 
 
 
4 (21) 
 
21-30 
 
 
6 (31.5) 
 
31-40 
 
 
2 (10.5) 
 
41-50 
 
 
3 (15.75) 
 
61-70 
 
 
3 (15.75) 
 
71-80 
 
 
1 (5.5) 
Mean age:34.79 years, Median:24, Standard deviation:18.677,Range:13-72. 
Male:Female ratio was 1.375:1. [Male-11, Female-8 ] 
 
TABLE SHOWING SYMPTOMS AND SIGNS IN PATIENTS WITH  
 
 SUBLEUKAEMIC LEUKAEMIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
The proportion 
of patients presenting with fever [52.6%] was significantly higher  in patients with 
subleukaemic leukaemia as compared  overall.[33.3%] 
 
HAEMATOLOGICAL PARAMETERS IN PATIENTS WITH 
SUBLEUKAEMIC 
 
LEUKAEMIA 
  
Hb g/dl 
 
TC cells/ cu.mm 
 
Platelets 
 
Clinical profile 
 
 
FREQUE
NCY 
 
PERCENTAG
E 
 
Easy fatiguability 
 
 
13 
 
68.4 
 
Breathlessness 
 
 
2 
 
10.5 
 
Fever 
 
 
10 
 
52.6 
 
Bleeding manifestations 
 
 
6 
 
31.5 
 
Pallor 
 
 
19 
 
100.0 
 
Splenomegaly 
 
 
2 
 
10.5 
 cells/cu.mm 
 
 
Mean 
 
 
7.026 
 
2152.63 
 
28052.63 
 
Median 
 
 
7.600 
 
2200.00 
 
17000.00 
 
Std. Deviation 
 
 
2.3909 
 
723.701 
 
23051.810 
 
Range 
 
 
2.3 – 9.9 
 
1000 - 3500 
 
2000 - 89000 
 
MCV  IN PATIENTS WITH SUBLEUKAEMIC LEUKAEMIA 
 
 
Mean 
 
 
91.276 
 
 
Median 
 
 
90.800 
 
Std. Deviation 
 
5.1800 
 
 
Range 
 
82.7 – 101.5 
 
 
BLOOD PICTURE IN PATIENTS WITH  SUBLEUKAEMIC 
LEUKAEMIA 
 
 FREQUENCY 
N = 18 
Normocytic 
normochromic 
 
4 (22.2 %) 
 
Microcytic 
Hypochromic 
 
 
1 ( 5.5 %) 
 
Macrocytosis 
 
4 (22.2%) 
  
Blasts 
 
9 (50%) 
 
50% of patients with subleukaemic leukaemia showed presence of blasts in blood 
picture. 11 [64.7 %] of the 17 patients with subleukaemic leukaemia had a 
hypocellular marrow. 
 
 
MEGALOBLASTIC ANAEMIA : 
 
Megaloblastic anaemia formed only a small group among the patient  population 
with  pancytopenia.[5.3% ]All the 8 patients were characterized as having B12 
deficiency. [serum B12  levels <200 pg/ml]  Peripheral neuropathy was noted in 5 
out of the 8 patients.[62.5%] 
 
 
  
MEGALOBLASTIC ANAEMIA AND PERIPHERAL NEUROPATHY   
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     PERIPHERAL 
  NEUROPATHY YES NO
   MEGALOBLASTIC     
         ANAEMIA 
      PRESENT  
   ABSENT  
 
    Fishers exact p value: 0.000 
    Odds ratio [OR]: 116.7 , CI: 15.8-861.4, p value:0.000 
     Peripheral neuropathy was much more likely to be present in those patients 
with megaloblastic      anaemia, than in those without megaloblastic anaemia 
.[OR:116.7 , CI: 15.8-861.4, p      value:0.000] 
      
 
SENSITIVITY AND SPECIFICITY OF MCV FOR  MEGALOBLASTIC ANAEMIA  
  4 14
4 107
  MCV YES NO
   MEGALOBLASTIC     
         ANAEMIA 
        >  100
       <  100 
 
 Fisher’s exact  p value[0.013] 
 Sensitivity:50%                Specificity:88% 
 Positive predictive value:22%   Negative predictive value:96% 
 
Mean Corpuscular Volume as a screening test for megaloblastic anaemia is more  
specific,but less sensitive.Negative predictive value is 96% indicating that if the   
MCV ≤  100,the probabililty of patient having megaloblastic anaemia is only 4 %.  
 
 
    SENSITIVITY AND SPECIFICITY OF HYPERSEGMENTED POLYMORPHS FOR DIAGNOSIS OF 
                               MEGALOBLASTIC ANAEMIA   
   4    6
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 HYPERSEGMENTED 
          PMN YES NO
   MEGALOBLASTIC     
         ANAEMIA 
      PRESENT 
   ABSENT  
 
 PMN – Polymorphonuclear cells 
 Fisher’s exact  p value[0.009] 
 Sensitivity:50%                Specificity:95% 
 Positive predictive value:40%   Negative predictive value:97% 
 Hypersegmented polymorphs as a screening test for megaloblastic anaemia is 
more  specific,but less sensitive.Negative predictive value is 97% indicating that 
if hypersegmented  polymorphs are absent, the probability of patient having 
megaloblastic anaemia is only 3 %.  
 
Bone marrow aspirate from a patient with Megaloblastic maturation 
 
 
 
 
DISCUSSION 
   
                    Peripheral pancytopenia may be a manifestation of a wide variety of 
disorders  which primarily or secondarily affect the bone marrow.The pattern of 
disease leading to pancytopenia is expected to vary in different population groups 
with their differences in  nutritional status, and prevalence of infective 
disorders.[1,3] In India the causes of  pancytopenia are not well defined. 
      
                    In the present study ,150 cases of  age varying from 13 years to 77 
years were  studied of which 93 were males and 57 were females.The incidence of 
pancytopenia was high in  the third,fourth and fifth decades. The commonest 
causes of pancytopenia in our patients were  aplastic anaemia [27.3%]  followed  
by hypersplenism [25.3%] and subleukaemic leukaemia.  [12.6%]. The most 
common presenting symptoms  were that of easy fatiguability [79.3%]  followed 
by  fever [33.3%] and bleeding manifestations [32.%].Examination wise pallor  
was a universal finding. Peripheral neuropathy was much more likely to be 
present in those  patients with megaloblastic anaemia, than in those without 
megaloblastic anaemia. MCV>100 fl   and presence of  hypersegmented 
polymorphs as a screening test have  high specificity[88% and  95 % respectively] 
and negative predictive value[96% and 97%  respectively] for patients with  
megaloblastic anaemia. Patients with tuberculosis and bone marrow infiltrative 
disorders were  much more likely to be  HIV infected.. [OR:30.95.  CI 5.8,156.3.  
p=0.000 and  OR:18.95  CI  4.3,73.2. p=0.000 respectively].The above data 
obtained from our study are compared with some other published studies. 
 
                        
                 SPECTRUM OF DISEASES CAUSING PANCYTOPENIA 
                
   STUDY             COUNTRY     YEAR     CASES  
COMMONEST  
                                                                                           
CAUSE                  
 
1. International                 Israel,                 1987           387          Aplastic anaemia 
Agranulocytosis               Europe.                                                  [57.7%] 
and aplastic   
Anaemia study 
 
2. Imbert et al                   France                 1989           213          Malignant 
myeloid  
                Disease [42%] 
 
3. Hussain M A et al        Bangladesh         1992           50            Aplastic anaemia 
 
4. Sen et al                        Rohtak                1996           191         Megaloblastic 
anaemia 
                [39%] 
 
5. Sauage et al                   Zimbabwe          1999           134          Megaloblastic 
anaemia                 
[35.02%]   
 
6. Kumar et al                   Chandigarh          2001          166          Aplastic 
anaemia  
                [29.5%] 
 
 
                     There are limited number of studies on the frequency of various 
causes of  pancytopenia.Limited data has been reported from the Indian 
subcontinent.The variation  in the frequency of various diagnostic entities causing 
pancytopenia has been attributed to  differences in methodology and stringency of 
diagnostic criteria ,geographic area, period  of observation ,genetic differences 
and varying exposure to myelotoxic agents.[1,3] 
 
                     The  prevalence of aplastic anaemia  varies from 10% to 52.7% 
.[1,3,28,29] of all  pancytopenic patients.Our  prevalence of aplastic anaemia was 
27.3%.The  prevalence of  hypersplenism in the present study was 
25.3%,compared to Kumar et al  series where prevalence  was 11.4%.  
 
                      The commonest cause of pancytopenia ,reported from various 
studies  throughout the world has been aplastic anaemia.[1,17] Most Indian 
studies however report  a high prevalence of megaloblastic anaemia. Kale et al [4] 
from Mumbai in a study of 65  pancytopenic patients detected megaloblastic 
anaemia in 25.4% of cases. Sen et  al [5] from Rohtak found megaloblastic 
anaemia to be the commonest cause [39%] in a  study of  191 pancytopenic 
patients. Tilak et al[3] found megaloblastic anaemia in 68%  of  the patients.This 
seems to reflect the higher prevalence of nutritional anaemia in Indian  
subjects.This is in sharp contrast with the results of our study where the 
commonest  cause of pancytopenia was aplastic anaemia  and the prevalence of 
megaloblastic anaemia  was only 5.3%. This may indicate improved nutritional 
status  accounting for the same. The  prevalence of megaloblastic anaemia varies 
from 0.8% to 68% [1,3,28,29] of  all  pancytopenic patients.  
 
                     AIDS  was diagnosed in 25.1% of the study cases in patients with  
multilineage  blood cytopenia  and  is now the commonest clinical condition 
associated with it  in a central  referral hospital in Zimbabwe.[30] In our study 
7.3% of the patients were found to be HIV seropositive,and the odds of having 
tuberculosis and infiltrative disorders were significantly  higher as compared to 
non-HIV infected individuals.Other causes of pancytopenia in HIV   infection 
include drug induced aplasia,cryptococcosis [31] and toxoplasmosis [32]. Hence, 
with increasing incidence of HIV infection ,a careful search for tuberculosis and 
other  infiltrative disorders is mandatory in immunocompromised individuals. 
 
                      The mean age in the present study was 40.34 years.Most of the 
patients were in  the third,fourth and fifth decade.Similar observations was made 
in Kumar et al.[33], but the  mean  age was 30.6 years.The maximum number of 
patients were seen under the age of 20  years [32.47%] in Tilak et al [3]series 
because they have included  paediatric patients in  their series. 
 
                         
                          The platelet count was less in aplastic anaemia group,as 
compared with other  groups.This observation was also noted with Kumar et al 
[33]  study.Bleeding manifestations were  also more common in aplastic anaemia 
group and platelet count in these patients were  <23000 cells/cu.mm.  
 
                          Bone marrow was predominantly hypocellular[44%] in contrast 
with Imbert et  al  [2] where 66% of the subjects had hypercellular marrow.This is 
probably explained by the  lower  prevalence of aplastic anaemia [10%] in the 
study population.  
 
                          The role of MCV and hypersegmented neutrophils as screening 
test for  megaloblastic anaemia were more specific and had a high negative 
predictive value. Sensitivity was  only  50% ,  in contrast to the study done by  
Osama Ishtiaq where it was 82% and 92.3%  respectively. [34] 
 
Limitations of the study: 
 
1. This study was carried out in a  tertiary care setting ; hence the various 
etiological conditions  for pancytopenia may not  reflect the prevalence in 
the general population. 
 
2. Bone marrow aspiration and biopsy could not be carried out in 
all subjects which is an essential investigation in  patients with 
pancytopenia.   
 
 
 
 
  
 
 
 
 
 
 
 
SUMMARY AND CONCLUSIONS 
 
1. The commonest causes of pancytopenia in our patients were aplastic 
anaemia [27.3%]       followed  by hypersplenism [25.3%] and 
subleukaemic leukaemia. [12.6%] 
 
2.  Symptom of anaemia [easy fatiguability] was the commonest presenting 
complaint. Pallor was a universal finding in all the patients. 
 
3. Patients with tuberculosis  and bone marrow infiltrative disorders were 
much more likely to be  HIV infected. 
 
4. Peripheral neuropathy was much more likely to be present in those 
patients with       megaloblastic   anaemia, than in those without 
megaloblastic anaemia . 
 
5. A  normal MCV and absence of hypersegmented neutrophils makes the 
diagnosis of        megaloblastic anaemia very unlikely.[NPV of  MCV≤ 
100 =96% and absence of        hypersegmented neutrophils=97 %] 
 
 
 
 
 
 
 
 
            . 
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                                                                APPENDIX 
 
PROFORMA 
            
 
           Serial Number:                                                       Hospital Number: 
 
           Name 
 
           AGE/SEX 
 
           Occupation 
 
           Address 
 
 
           Presenting complaints: 
                                                             Present/Absent                            Duration 
1. Easy fatigability 
 
2. Breathlessness 
                                                                                                                                                        
3. Palpitation 
 
4. Chest pain 
           
5. Swelling of limbs 
 
6. Fever 
            
           7.  Sore throat 
            
           8.  Bone pains 
           
           9.  Bleeding tendencies 
           
          10. Others 
 
           Past History: 
            
           Drug intake 
 
           Blood transfusions 
 
           Jaundice 
 
           Radiation exposure 
 
           Similar complaints 
 
           Admission to hospital 
 
           Family History: 
 
            Similar complaints 
          
         Bleeding tendencies 
            
           Personal History: 
 
           Diet               Appetite             Habits         Bowel/Bladder 
 
           Consanguinity 
 
           Menstrual cycle 
 
           Obstetric History [Miscarriage/IUGR] 
 
           GENERAL EXAMINATION: 
 
           Built        Nourishment        Pallor        Icterus        Edema         
Lymphadenopathy 
 
           Bone tenderness          Gum hypertrophy        Glossitis            Koilonychia 
 
           Bleeding manifestations              Hyper-pigmented knuckles 
 
           Vitals: 
 
 
           SYSTEMIC: 
 
           Abdomen: Organomegaly/Free fluid 
                             
            CVS 
 
             RS 
 
             CNS: Reflexes 
 
                       Plantar 
 
                       Sensory system 
 
 
           INVESTIGATIONS: 
            
           Essential investigations in all cases- 
 
           Hemoglobin        Total count          Differential count 
 
           Platelets 
 
           Blood picture 
 
           Reticulocytes 
 
           MCV 
          
          Bone marrow 
 
 
     Others: 
           Creatinine        RBS        Urine routine 
 
                       LDH                 LFT 
 
                       B12                   Folic acid 
 
                       HIV                  ANA/Anti-ds DNA 
 
                       Hams test          Protein electrophoresis 
                   
                      Chest x ray        U/S  A bdomen 
 
 
 
 
                                                            
 
 
 
                                                            CONSENT FORM. 
 
              Title of study: A study of etiology and clinicopathological profile of  
pancytopenia. [Descriptive study] 
 
               Institution: Department of Medicine, CMC Hospital. 
                Purpose of study: You are being asked to take part in a clinical study to 
know  the  cause of decrease in blood components-red blood cells, white blood 
cells and  platelets. 
 
               Confidentiality: Your records and all details obtained in this study will 
remain  strictly confidential at all times, but will need to be available to the doctor 
conducting the  study. Your identity will not otherwise be revealed. Your personal 
data collected will be only in connection with this study .You will not be referred 
to by name or identified in  any report or publication. 
 
               Consent: I have read the above information before signing this consent 
form. 
 
 
               Signature of subject 
 
 
 
 
 
 
 
 
 
 
 
 
           
     GLOSSARY TO MASTER CHART 
 
Sn-Serial Number  hn-Hospital Number name-Name age-Age     
agec-Age Category 1. 13-20  2. 21-30  3.  31-40  4. 41-50  5.  51-60     
6.61-70  7.   71-80 
sex-Sex (1.Male,2.Female)   
A.  ef-Easy fatiguability  B.bpn-Bony pain C.sot-Sore throat  D.pap-Palpitation  
E.boe-Breathlessness on exertion  F.fev-Fever G.btn-bleeding tendency  H. low-
Loss of weight I.phd- past history of drugs J.pal-Pallor K.ict-Icterus 
L.lne.Lymphadenopathy M.ede-Edema N.hep-Hepatomegaly.O.spl-Splenomegaly 
P.asc-Ascitis Q.pn-Peripheral Neuropathy  
A – Q     1.Present    2.Absent 
 hcat-Hemoglobin category (<4)-1    (4.1-7) –2    (7.1-10)- 3  
 hb-Hemoglobin  in g/dl 
 tcat-Total Leucocyte count category  (<1000)-1 (1001-2000)-2  (2001-3000)-3  
(3001-4000)-4 
 tc- Total Leucocyte count  per Cubic millimeter  
 pcat-Platelet count category (<20000)-1  (21000-50000)-2   (51000-100000)-3  
bpic-Blood picture (1)-Normocytic Normochromic (2)-Microcytic Hypochromic 
(3)-Macrocytosis                                                       
         (4)-Blasts  
 ret-Reticulocyte count     mcv-Mean corpuscular volume in fl 
 bm-Bone marrow (1)-Hypocellular (2)-Hypercellular   
R.hiv –HIV ELISA   S.hbs-HBSAg    T.hcv-HCV antibody  U.hms-Hams acid 
serum test   
R – U  1 Positive    2 –Negative  
V. b12-Serum vitamin B12   W.fa-Serum Folic acid   V – W  1-Normal  2-Low  
 etio-Etiology of Pancytopenia   1- Aplastic anaemia   2. Myelodysplastic 
syndrome 
3. Subleukaemia leukaemia 4. Hypersplenism 5. Megaloblastic anaemia   6. 
Infiltrative disorders 
7. Sepsis  8. Systemic lupus erythematosus 9. Unknown 
 
dsis-Diagnosis  1-Idiopathic Aplastic anaemia  2.Drug induced Aplastic anaemia 
3.Systemic lupus erythematosus 4.Myelodysplastic syndrome 5.Acute myeloid 
leukaemia 6. Acute lymphoid leukaemia 7. Hairy cell leukaemia 8.Portal 
Hypertension 9. Kala azar 10. Hemolytic anaemia 11.B12 deficiency 
12.Tuberculosis 13.Non Hodgkins lymphoma. 14.Multiple myeloma   
15.Cryptococcusis 16.HIV infection 17.Idiopathic 18.HCV positive 
 
sn hn name age agec sex ef bpn sot pap boe fev btn low phd pal ict lne ede hep spl asc pn hcat hb tcat tc pcat plt bpic ret mcv bm hiv hbs hcv hms b12 fa etio dsis
1 602025 CHAYA 56 5 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 2 2 3 7.5 2 1800 2 50000 1 2.62 91.6 2 2 2 2 . . . 4 8
2 626477 JHUMA 16 1 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 2 4.4 2 2000 1 5000 2 2.64 83.4 1 2 2 2 . . . 1 1
3 612282 S RAJA 71 7 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 3.8 2 1300 1 18000 3 3.26 95.4 2 2 . . . 2 1 5 11
4 612840 SARAV 23 2 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 4.8 3 2300 1 7000 2 2.21 81.8 1 2 1 . . . . 2 4
5 600998 JEYA 24 2 2 1 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2 1 2.3 1 1000 1 2000 4 2.28 93.6 1 . . . . . . 3 5
6 614459 V LAXM 34 3 2 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 3.9 3 2300 1 12000 3 5.3 94.1 1 . . . . . . 3 5
7 617259 GANES 77 7 1 1 2 2 2 1 2 2 2 2 1 2 2 1 2 1 2 2 1 3.1 3 2900 3 99000 2 2.27 63 2 . . . . . . 4 17
8 617215 CHAND 15 1 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 1 4 2 2000 2 46000 2 . 73.4 2 2 2 2 . . . 4 17
9 618710 AHMED 41 4 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 6.4 3 2700 1 5000 1 0.99 85.6 1 2 2 2 2 . . 1 1
10 625941 MUTHU 28 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 7.7 3 2600 1 12000 3 1.62 96.6 1 2 2 2 . . . 1 1
11 626061 PRERA 17 1 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 3 9.7 3 2800 2 44000 . . . 1 . . . . . . 3 6
12 627356 RATAN 41 4 1 1 2 2 2 2 1 1 1 2 1 2 1 2 1 1 1 1 3 9.2 3 2200 1 14000 2 2.67 68.7 1 2 2 2 . . . 7 17
13 628111 MANUV 42 4 1 1 2 2 2 2 2 2 2 2 1 2 1 1 2 2 1 2 2 6.1 3 2400 3 96000 2 4.05 72.5 2 1 2 . . . . 6 12
14 630077 BISWAJ 18 1 1 1 2 2 2 2 2 2 2 2 1 1 2 1 1 1 2 2 2 5 3 2300 1 14000 2 1.05 76.7 2 2 2 2 2 . . 4 10
15 629619 SHAHN 35 3 2 1 2 2 2 2 1 2 2 2 1 1 2 2 1 1 2 2 1 3.6 1 900 3 61000 3 3.67 110.4 2 2 2 2 . . . 2 4
16 628610 ASHA 24 2 2 1 2 2 2 2 2 2 1 1 1 2 2 2 2 2 2 2 3 8.4 3 2400 1 15000 1 1.14 83.3 2 2 2 2 . . . 3 5
17 628618 SONAM 47 4 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 9.5 3 2100 1 9000 1 0.52 86.9 1 2 2 2 . . . 1 1
18 612459 SHIV K 24 2 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 5.4 3 2900 1 8000 3 3.67 106.4 1 2 2 2 . . . 2 4
19 581614 JALEEL 54 5 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.4 4 3700 1 6000 1 0.64 95.8 1 2 2 2 . . . 1 1
20 580846 BAL B C 45 4 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 3 8.1 3 2600 1 20000 3 2.03 99.2 1 2 2 2 . . . 1 1
21 602111 SHOBA 60 5 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 1 2 2 3 9.1 3 3000 3 96000 2 . 84.4 2 2 2 2 . . . 4 17
22 579487 SALMA 24 2 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.1 3 2200 1 4000 1 1.38 92.5 1 2 2 2 . . . 1 1
23 586126 NAGAIA 72 7 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 6.8 2 2000 2 49000 4 0.86 90.8 . 2 . . . . . 3 5
24 636017 RAJESW 65 6 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 4.4 2 1800 1 2000 1 . 92.9 1 . . . . . . 1 1
25 635029 GANDH 43 4 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 1 3.8 3 2400 1 3000 2 1.77 75.1 1 2 2 2 . . . 1 1
26 631093 S VANI 29 2 2 2 2 2 2 2 2 1 2 2 1 2 2 1 2 1 1 2 2 4.3 2 1500 2 33000 2 1.91 70.8 2 2 2 2 . . . 4 17
27 633734 PINJRA 60 5 2 1 2 2 2 2 1 2 1 2 1 2 2 2 2 1 2 2 3 8.7 4 3200 3 71000 1 . 82.8 2 2 2 2 . . . 6 13
28 626811 PULMA 55 5 2 1 2 2 2 1 2 1 2 2 1 2 2 2 2 2 2 2 3 8.1 3 2300 1 10000 1 1.97 84.7 1 2 2 2 . . . 1 1
29 630520 BABU 31 3 1 2 2 2 2 1 1 2 1 2 1 2 2 2 2 2 2 2 3 7.2 4 3500 3 99000 . . . 2 1 2 2 2 2 . 9 16
30 630724 SORNA 64 6 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 9.9 3 2300 1 10000 . . . 1 2 2 2 . . . 1 1
31 625234 SUBHA 42 4 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 2 2 3 9.8 2 1200 1 14000 2 2.74 87.5 2 2 2 2 . . . 4 8
32 626592 ANU DE 25 2 2 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2.2 3 2700 1 8000 1 4.12 92.8 1 2 2 2 2 . . 1 1
33 621181 P SING 37 3 1 1 2 2 2 2 1 2 2 2 1 1 2 1 2 1 1 2 3 8.1 2 1700 1 9000 2 4.25 67.5 2 2 2 2 . . . 4 17
34 628267 RANI BA 64 6 2 1 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 2 3 7.1 2 1600 1 18000 2 1.36 79.5 2 2 2 2 . . . 6 13
35 600623 GOWRI 25 2 2 1 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 2 3 8 2 1200 1 16000 1 . 88.1 1 2 2 2 . . . 1 2
36 602440 NONGS 30 2 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 3 8.1 2 1400 3 69000 1 3.22 92.7 1 1 2 2 . 1 1 9 16
37 606567 LOCHA 29 2 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 5.8 3 2100 1 3000 3 1.33 93.9 1 2 2 2 . . . 1 1
38 611136 EBASE 15 1 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 6.3 3 2500 1 5000 2 3.23 86.9 1 2 2 2 . . . 1 1
39 589469 S RAYU 38 3 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 1 2 6.4 3 2100 2 32000 3 . 95.7 2 . . . . . . 5 11
40 593003 S DEVI 32 3 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 2 4.8 2 1800 3 51000 2 . 70 2 2 2 2 . . . 4 8
41 595540 S KUND 13 1 2 2 2 2 2 2 1 1 1 2 1 2 2 2 2 2 2 2 3 9.6 3 2200 2 27000 4 0.3 85.8 2 2 2 2 . . . 3 6
42 595281 M DEBN 59 5 1 1 2 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 6.5 3 2700 2 41000 . . . 2 2 2 2 . . . 9 17
43 600811 M SING 63 6 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 8.6 2 1400 1 8000 1 2.32 87.9 1 2 2 2 . . . 3 5
44 611280 SHAFE 17 1 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.9 3 2600 1 8000 3 0.33 100.2 1 2 2 2 . . . 1 1
45 609514 BASHA 49 4 2 1 2 2 2 1 2 1 2 2 1 2 2 2 2 2 2 2 3 8.4 4 3200 1 16000 3 3.93 . 1 2 2 1 . . . 1 1
46 614464 S RAJW 42 4 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 3 7.4 2 1500 3 100000 2 1.73 79.1 2 2 2 2 . . . 2 4
47 614481 A MALL 18 1 2 1 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 2 5.9 2 1900 2 58000 2 3.79 77.3 1 2 2 2 . . . 8 3
48 615515 RAMAD 47 4 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 7.7 4 3500 1 6000 1 1.34 88.3 1 2 2 2 . . . 1 1
49 617645 H DAS 40 3 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 5.4 2 1300 1 7000 2 1.44 82.1 1 2 2 2 . . . 2 4
50 618504 S DEVI 70 6 2 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 3 8.4 3 2800 1 11000 1 . . 1 2 2 2 . . . 9 12
51 619290 SAROJA 49 4 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 3 7.6 3 2300 3 59000 2 1.3 79.1 2 2 2 2 . . . 4 8
52 619567 KAVITH 19 1 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 1 3.4 4 3300 2 29000 3 2.46 115.8 2 . . . . 2 1 5 11
53 619551 K PURT 45 4 2 1 2 2 2 2 1 2 1 2 1 2 1 1 1 1 2 2 2 4.6 4 3400 2 29000 2 2.34 79 2 2 2 2 . . . 6 13
54 621869 HAZI M 64 6 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 4.7 4 3100 2 24000 3 2.31 94.2 2 2 2 2 . . . 3 5
55 622278 R SWA 53 5 1 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 6.6 2 1800 1 17000 2 . 83.4 1 2 2 2 . . . 1 2
56 621611 RAJAN 48 4 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 3 9.6 3 2300 2 41000 1 3.79 89.2 2 2 2 2 . . . 5 11
57 625674 R MAIT 19 1 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 5.5 3 2500 2 23000 3 4.39 110.3 1 . . . 2 1 1 1 1
58 608669 RADHA 23 2 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 3 7.2 2 1200 1 17000 4 0.88 89.1 1 2 2 2 . . . 3 5
59 609495 N TAMA 32 3 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 3 9.4 3 2700 3 98000 1 0.37 91.6 2 1 2 2 . 1 1 9 16
60 607974 F MAHA 45 4 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 3 7.3 4 3400 3 86000 2 . . 2 2 2 2 . . . 6 14
61 609073 MANOJ 25 2 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 5.1 3 2200 1 10000 2 1.87 86.8 1 2 2 2 2 . . 1 1
62 609629 J PAUL 25 2 2 1 2 2 2 2 2 2 2 2 1 1 2 1 2 1 1 2 3 7.7 2 1300 2 31000 3 5.57 94.5 2 2 2 2 . . . 4 8
63 610411 DAYALA 35 3 1 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 4.4 2 1300 1 7000 3 3.37 112.1 1 2 2 2 . . . 1 1
64 607505 JAGAT 37 3 1 1 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 2 2 4.7 2 1200 2 30000 . . 81.4 2 2 1 2 . . . 4 8
65 610371 K C KA 65 6 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 5.6 3 2800 2 46000 2 . 68.4 2 2 2 1 . . . 9 18
66 600339 KUYAR 35 3 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.9 2 1800 1 13000 3 0.57 92.1 1 2 2 2 . . . 1 1
67 600596 JOSEP 27 2 1 1 2 2 2 1 1 2 1 2 1 2 1 1 1 1 2 2 2 5.5 4 3100 3 87000 2 6.35 77.2 2 1 2 2 . . . 6 12
68 606233 AHAMA 45 4 1 1 2 2 2 1 2 2 2 2 1 2 2 2 1 2 2 2 3 8.9 1 1000 2 27000 1 0.62 88.6 2 2 2 2 . . . 2 4
69 603889 KARAN 22 2 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.2 3 2600 1 9000 1 0.94 87.7 1 2 2 2 . . . 1 1
70 604806 C DAS 28 2 2 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 3 9 3 2500 3 98000 3 4.96 102.5 2 . . . . . . 5 11
71 608437 SS PRA 65 6 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 5.8 3 2700 1 7000 1 1.23 80.3 1 2 2 2 . . . 1 1
72 598203 BASUD 61 6 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 3 8.5 2 1300 3 89000 3 2.65 101.5 1 . . . . . . 3 5
73 579886 M BISW 62 6 1 1 2 2 2 2 1 2 2 2 1 1 2 2 2 1 2 2 3 10 3 2800 3 55000 1 0.93 89.1 2 2 2 2 . . . 4 7
74 578509 PZ BEG 44 4 2 1 2 2 2 1 2 1 2 2 1 1 2 2 1 2 2 2 2 4.7 2 1600 1 9000 3 5.38 97 2 2 2 2 2 . . 2 4
75 587609 G DEVI 22 2 2 2 2 2 2 2 1 2 1 2 1 2 2 2 2 1 2 2 2 5.9 3 2100 3 83000 2 . 79.1 2 . . . . . . 4 9
76 587557 M GOR 32 3 2 1 2 2 2 1 2 1 2 2 1 2 2 2 2 2 2 2 2 5.8 4 3300 1 10000 3 2.55 95.7 1 . . . . . . 1 1
77 586512 D NATH 65 6 1 1 2 2 2 1 2 2 1 2 1 2 2 1 1 1 1 2 2 6.8 4 3100 2 29000 2 . . 2 2 2 2 . . . 4 8
78 586472 S SARD 37 3 1 2 2 2 2 1 2 1 2 2 1 2 2 2 2 2 2 2 3 7.1 4 3900 1 6000 3 3.26 103.6 1 2 2 2 . . . 1 1
79 586452 ARCHA 22 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 9.9 3 2100 2 46000 4 0.9 90.1 2 2 2 2 . . . 3 5
80 594857 ITTOOP 75 7 1 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 3 8.9 3 2200 1 15000 1 . 88.4 1 . . . . . . 1 1
81 596709 S GHOS 48 4 2 1 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 2 2 4.2 2 1600 1 6000 2 0.6 77.1 1 . . . . . . 1 2
82 595695 BABI D 21 2 1 1 2 2 1 2 1 1 1 2 1 2 2 2 2 2 2 2 2 6.8 2 1700 1 3000 1 0.32 85.6 1 . . . . . . 1 1
83 597355 MUMMU 63 6 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 3 7.4 4 3600 1 11000 1 1.9 90.4 1 2 2 2 . . . 1 1
84 601930 M DAS 38 3 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 7.3 4 3300 1 7000 3 1.5 108.3 1 2 2 2 . . . 1 1
85 601709 S MALL 38 3 1 1 2 2 2 2 1 1 2 2 1 2 2 2 1 2 2 2 3 8.6 4 3200 1 4000 1 0.99 90.3 1 2 2 2 . . . 2 4
86 601698 JAFAR 23 2 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 3.7 3 2600 1 3000 1 3.1 92.6 1 2 2 2 . . . 1 1
87 601677 AMLA 16 1 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 1 2 2 3 8.7 4 3500 1 16000 4 . 92.2 2 2 2 2 . . . 3 6
88 628362 P DAS 43 4 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 3 7.5 4 3800 2 43000 2 4.46 77.2 2 2 2 2 . . . 4 8
89 601033 SIVA S 21 2 1 1 2 2 2 2 1 1 1 2 1 2 2 2 2 2 2 2 1 4 2 1200 1 6000 1 1.24 84.9 1 2 2 2 . . . 1 1
90 625310 MS HOS 48 4 1 1 2 2 2 2 2 1 2 2 1 2 2 1 2 2 2 2 3 8.3 3 2900 1 5000 1 1.3 87.6 1 2 2 2 . . . 1 1
91 629061 SHANT 20 1 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 1 2 2 2 4.2 2 1700 3 83000 2 2.69 58.6 2 2 2 2 . . . 4 8
92 629279 SHAMA 40 3 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 8.1 4 3400 1 4000 1 2.62 91.8 1 2 2 2 . . . 1 1
93 633224 SIVAKU 34 3 1 1 2 2 2 2 2 2 1 2 1 2 1 2 1 2 2 2 2 6.7 2 1200 3 57000 . 0.78 . 2 1 2 2 . . . 6 15
94 634369 SANWA 18 1 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 1 2.3 3 2600 1 5000 1 2.75 91.4 1 2 2 2 . . . 3 5
95 636097 SUDAK 37 3 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 1 2 3 2400 1 1000 3 . 95.2 1 . . . . . . 1 1
96 637149 P RAJU 69 6 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 8.4 2 1500 2 22000 1 2.06 83.9 2 . . . . . . 2 4
97 586082 L BISW 45 4 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 3.8 3 2300 1 6000 2 3.61 107.7 1 2 2 2 . . . 1 1
98 581999 A BHAN 45 4 1 1 2 2 2 2 1 2 1 2 1 1 2 1 2 2 2 2 3 9.6 3 2300 1 5000 1 0.37 87.3 1 2 2 2 . . . 6 13
99 599144 S BUNG 33 3 2 1 2 2 2 2 2 2 1 2 1 1 2 1 2 2 1 2 3 9.3 3 2800 2 22000 . . 88.3 2 1 1 2 . . . 6 12
100 596141 R MAHA 60 5 1 1 2 2 2 2 1 2 2 2 1 2 2 1 2 1 2 2 3 7.4 2 1700 3 54000 2 2.46 81.9 2 2 2 2 . . . 4 9
101 593302 M RAJ 47 4 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 3 8.3 4 3500 2 22000 1 . 91.4 1 2 2 2 . . . 6 12
102 595543 V RAO 31 3 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 9 4 3500 3 100000 1 1.89 90.7 2 2 2 2 . . . 2 4
103 590058 MUTHU 56 5 1 2 2 2 2 2 1 1 2 2 1 1 2 2 2 2 2 2 3 9.9 1 400 3 79000 1 0.51 83.2 1 . . . . . . 2 4
104 589090 C SEKA 51 5 1 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 1 1 3.7 3 2300 2 38000 3 1.48 106 2 . . . . 2 2 5 11
105 597169 J KUMA 23 2 1 2 2 2 2 1 1 1 2 2 1 2 2 2 2 2 2 2 3 7.6 3 2500 3 66000 4 0.67 . 2 . . . . . . 3 5
106 581342 K KUKR 49 4 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 3 7.4 3 2100 2 18000 1 0.37 84.7 1 2 2 2 2 . . 1 1
107 589289 NATRA 67 6 1 1 2 2 2 2 1 2 2 2 1 2 2 2 1 2 2 2 2 6.9 4 3400 1 6000 1 0.86 89.2 2 . . . . . . 2 4
108 586330 ROHIT 17 1 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 5.4 3 2700 1 3000 1 0.88 82.7 1 2 2 2 . . . 1 1
109 591341 PRAMO 56 5 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 3 9.6 3 3000 2 48000 3 2.62 106.7 . 2 2 2 . . . 4 8
110 591325 KAMAL 40 3 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 2 3 9.2 3 2500 3 70000 . . . . 2 1 2 . . . 4 8
111 592453 R JAN P 29 2 2 1 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 2 1 3.9 3 3000 3 99000 . . . . 2 2 2 . . . 4 8
112 611309 MAYA D 58 5 2 1 2 2 2 2 2 1 1 2 1 2 2 1 2 1 2 2 3 7.8 3 2900 3 76000 . . 97.1 . 2 2 1 . . . 4 8
113 592943 H MON 38 3 1 2 2 2 2 2 1 2 1 2 1 2 2 1 2 1 1 2 3 8.8 3 2800 2 34000 3 2.6 95.3 . 2 1 2 . . . 4 8
114 603685 PADMA 38 3 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 1 2 1 3 7.6 4 3400 3 84000 3 3.98 104 . . . . . 2 1 5 11
115 599267 BALA S 50 4 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 4.4 4 3300 1 9000 1 3.98 93.3 . 2 2 2 . . . 9 17
116 597744 M KAUR 35 3 2 1 2 2 2 2 2 1 1 2 1 2 2 2 2 1 2 2 2 6.5 4 3700 3 74000 1 . . . 2 2 2 . . . 4 8
117 594398 P DUTT 34 3 1 1 2 2 2 2 1 2 2 2 1 1 2 2 2 1 2 2 2 5.7 2 1700 2 35000 1 2.25 79.1 . 2 2 1 . . . 4 10
118 587564 K LAMA 40 3 1 1 2 2 2 2 2 2 1 2 1 1 2 1 1 1 1 2 3 9.6 2 2000 2 42000 3 2.41 105.6 . 2 1 2 . . . 4 8
119 593186 R SING 40 3 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 3 7.8 4 3700 3 93000 . . . . . 2 . . . . 8 3
120 586041 A DUTT 65 6 1 1 2 2 2 2 2 1 2 2 1 2 2 1 2 1 2 2 3 8.9 3 2700 2 41000 . . 68.3 . 2 2 1 . . . 4 8
121 600556 CINAKK 63 6 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 3 9 3 2300 2 50000 . 0.97 79 . . . . . . . 7 19
122 607310 D SWA 65 6 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 2 3 7.2 3 2400 2 34000 . . 73.3 . 2 2 2 . . . 4 8
123 610103 SETUA 50 4 2 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 3 8.7 4 3300 3 70000 2 . 82.9 . 1 2 2 . . . 9 16
124 610380 R AHME 27 3 1 2 2 2 2 2 2 1 2 2 1 1 2 2 2 1 2 2 3 8.5 2 2000 2 40000 . . 73 . 2 2 2 . . . 4 8
125 582523 A KANT 58 5 1 1 2 2 2 2 2 2 1 2 1 2 2 1 2 1 2 2 3 9.8 4 3800 2 27000 . . . . 2 2 2 . . . 4 8
126 637802 SENTH 18 1 1 2 2 2 2 2 1 1 2 2 1 2 2 2 2 1 2 2 3 8.5 3 2700 2 45000 . . . . 2 2 2 . . . 4 8
127 599200 S REDD 25 2 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1 2 2 3 8.6 4 3800 1 10000 3 5.55 109.3 1 2 2 2 2 . . 9 17
128 625876 J KARJ 48 4 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 2 1 2 3 8.9 3 2700 3 80000 . . 77.9 . 2 2 2 . . . 4 8
129 620612 A RANI 52 5 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 8.2 3 2100 2 43000 . . . . 2 1 2 . . . 9 20
130 614983 R REDD 43 4 1 1 2 2 2 2 2 2 1 2 1 2 1 2 2 2 2 2 3 8.8 4 3600 3 76000 2 . 74.2 . 1 2 2 . . . 6 12
131 612747 S DEVI 30 2 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2 1 2 2 6.4 2 1800 3 90000 . . . . 2 2 2 . . . 9 17
132 633820 SWAPA 43 4 1 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 2 3 8.5 1 1000 2 45000 . . . . 2 2 2 . . . 4 8
133 626565 VALAR 37 3 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 2 2 4.1 2 1900 2 34000 2 1.72 55.1 . . . . . . . 4 8
134 629415 SHANK 39 3 1 1 2 2 2 2 2 1 2 2 1 2 2 1 2 1 1 2 1 3.4 3 2400 3 55000 2 3.92 82.6 . 2 2 2 . . . 4 8
135 608389 N C PA 65 6 1 1 2 2 2 2 2 2 1 2 1 1 2 1 2 1 2 2 3 9.4 4 3100 2 47000 3 . 96.7 . 2 1 2 . . . 4 8
136 610103 SETUA 50 4 2 1 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 2 3 8.7 4 3300 1 15000 2 . 82.9 . 1 2 2 . . . 9 16
137 611173 JENIFA 17 1 2 2 2 2 2 2 1 2 1 2 1 2 1 2 2 2 2 2 3 8.3 2 1600 2 50000 2 . . . 2 2 2 . . . 6 12
138 580590 D RAJ 50 4 1 1 2 2 2 2 2 2 1 2 1 1 2 2 2 1 2 2 3 9.9 2 2000 3 67000 2 1.54 77.2 . 2 1 2 . . . 4 8
139 646138 BADRU 40 3 2 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 4.7 1 700 2 24000 2 2.35 60.4 2 . . . . . . 9 17
140 646275 SETAM 62 6 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 3 9.2 4 3200 1 20000 3 2.64 106.2 1 2 2 2 . . . 2 4
141 646613 R MEHT 37 3 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 3 8.2 2 1600 3 95000 2 2.41 66.1 2 2 2 2 . . . 5 11
142 642656 C RAO 44 4 1 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 2 5.5 2 1900 1 16000 1 . 88.5 1 2 2 2 . . . 3 5
143 645213 S MANS 47 4 1 1 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 5.2 3 2300 1 11000 3 0.96 94.8 1 2 2 2 . . . 3 5
144 645318 D DAS 32 3 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 3 8.3 2 1700 2 21000 4 . 101.1 . 2 2 2 . . . 3 5
145 642717 B MAND 42 4 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1 2 2 3 7.3 2 1300 1 16000 2 2.19 82.7 1 . . . . . . 3 6
146 641731 P K DAS 34 3 1 1 2 2 2 2 1 2 1 2 1 2 1 1 1 1 2 1 2 6.1 2 1100 3 69000 2 1.92 . 2 1 2 2 . . . 6 12
147 641854 IZARAL 29 2 1 2 2 2 2 2 1 2 2 2 1 2 2 2 1 1 2 2 2 6.9 3 2500 3 69000 1 4.75 90.7 2 2 2 2 . . . 4 21
148 641312 A PRIYA 22 2 2 2 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 3 9 4 3300 2 49000 4 3.8 90.6 1 2 2 2 . . . 3 5
149 643243 K ROY 18 1 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 5.5 2 1700 1 5000 2 2.72 74.8 1 2 2 2 . . . 1 1
150 642499 NAGAR 24 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 5 4 3500 1 9000 3 2.5 97 1 . . . . . . 2 4
